WO2003014342A2 - Identification of a dna variant associated with adult type hypolactasia - Google Patents
Identification of a dna variant associated with adult type hypolactasia Download PDFInfo
- Publication number
- WO2003014342A2 WO2003014342A2 PCT/EP2002/008963 EP0208963W WO03014342A2 WO 2003014342 A2 WO2003014342 A2 WO 2003014342A2 EP 0208963 W EP0208963 W EP 0208963W WO 03014342 A2 WO03014342 A2 WO 03014342A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid molecule
- sequence
- gene
- adult
- Prior art date
Links
- 208000028116 lactose intolerance adult type Diseases 0.000 title claims abstract description 67
- 108700016491 Adult Type Lactose Intolerance Proteins 0.000 title claims abstract description 62
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 172
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 152
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 152
- 102100040402 Phlorizin hydrolase Human genes 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 239000002773 nucleotide Substances 0.000 claims abstract description 52
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 52
- 230000000295 complement effect Effects 0.000 claims abstract description 35
- 238000012360 testing method Methods 0.000 claims abstract description 31
- 238000004458 analytical method Methods 0.000 claims abstract description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 18
- 239000002157 polynucleotide Substances 0.000 claims abstract description 18
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 18
- 230000000968 intestinal effect Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 108090000604 Hydrolases Proteins 0.000 claims abstract description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108020004414 DNA Proteins 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 30
- 238000009396 hybridization Methods 0.000 claims description 28
- 238000003752 polymerase chain reaction Methods 0.000 claims description 26
- 201000010538 Lactose Intolerance Diseases 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 23
- 230000003321 amplification Effects 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 22
- 108091023037 Aptamer Proteins 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 238000001415 gene therapy Methods 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 102000004157 Hydrolases Human genes 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 210000003754 fetus Anatomy 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 210000004209 hair Anatomy 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 12
- 108010059881 Lactase Proteins 0.000 description 60
- 108010005774 beta-Galactosidase Proteins 0.000 description 60
- 230000002688 persistence Effects 0.000 description 58
- 229940116108 lactase Drugs 0.000 description 55
- 239000013615 primer Substances 0.000 description 54
- 108700028369 Alleles Proteins 0.000 description 42
- 102000054766 genetic haplotypes Human genes 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000002085 persistent effect Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 101150088918 Mcm6 gene Proteins 0.000 description 12
- 239000003550 marker Substances 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002987 primer (paints) Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091092878 Microsatellite Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 6
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 101100434523 Bos taurus ADGRL2 gene Proteins 0.000 description 4
- 108010001394 Disaccharidases Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100028820 Aspartate-tRNA ligase, cytoplasmic Human genes 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108010059801 Lactase-Phlorizin Hydrolase Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000696909 Homo sapiens Aspartate-tRNA ligase, cytoplasmic Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010060926 abdominal symptom Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002575 gastroscopy Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 101100518161 Arabidopsis thaliana DIN4 gene Proteins 0.000 description 1
- 108010065272 Aspartate-tRNA ligase Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100034505 Ceroid-lipofuscinosis neuronal protein 5 Human genes 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004332 Citrus madurensis Nutrition 0.000 description 1
- 235000007438 Citrus mitis Nutrition 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108700016492 Congenital Lactase Deficiency Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
- 101000710208 Homo sapiens Ceroid-lipofuscinosis neuronal protein 5 Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101001038051 Homo sapiens Phlorizin hydrolase Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282515 Papio hamadryas Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000512294 Thais Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000005161 congenital lactase deficiency Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000003977 dairy farming Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000007394 diastrophic dysplasia Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- -1 olive oil Chemical compound 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000018412 transposition, RNA-mediated Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01062—Glycosylceramidase (3.2.1.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a nucleic acid molecule comprising a 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene contributing to or indicative of the adult-type hypolactasia
- said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, the sequence of SEQ ID NO:1 is also depicted in Fig. 4 and comprised in the sequence as depicted in Fig. 8; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 2, the sequence of SEQ ID NO:2 is also depicted in Fig.
- LPH intestinal lactase-phlorizine hydrolase
- lactase persistence a condition known as lactase persistence.
- the phenotype lactase persistence/non- persistence has been shown to be genetically determined, the persistent status being dominant over the non-persistent status 4"6 .
- hypolactasia in children is justified if the histology of the intestinal biopsy is normal and lactase activity is less than 20U/g protein and lactase/sucrase ratio less than 0.30, or in the LTT with ethanol administration a maximum rise in blood glucose concentration of less than 20mg/100ml and in galactose concentration of 5mg/100 ml or less (Sahi et al, 1972) is demonstrated.
- the current methods to diagnose adult-type hypolactasia are laborious. LTT is inexact and therefore, an invasive procedure, gastroscopy is needed before the diagnosis can be ascertained. Since adult-type hypolactasia is very common and the major cause of nonspecific abdominal symptoms (in one third of patients complaining stomach pain), there is a clear need to improve the diagnostics of this common health problem.
- nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 5' from the LPH gene a cytosine residue
- nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 5' from the LPH gene a guanine residue.
- Hybridization is usually followed by washing to remove unspecific signal. Washing conditions include conditions such as 65°C, 0.2xSSC and 0.1% SDS or 2xSSC and 0,1% SDS or 0,3XSSC and 0,1% SDS at 25°C - 65°C.
- the present invention also relates to a hybridizing nucleic acid molecules of at least 20 nucleotides; see (c) and (d) herein above. Yet, the present invention also relates to a nucleic acid molecule of at least 50, at least 100, at least 150, or at least 200 nucleotides. Preferably, said hybridizing fragments comprise at least 25, at least 50, or at least 75 nucleotides, at least 100 nucleotides, 5' and 3' of the position -13910 as defined in (c) or of position -22018 ad defined in (d) herein above.
- MCM6 is a member of a gene family (MCM 2-7), required for the initiation of DNA replication ensuring that it takes place only once during the cell cycle 31 .
- MCM6 unlike LPH, is not restricted in its tissue distribution and there is no correlation in the levels of MCM6 and LPH transcripts 18 .
- the invention further relates to a nucleic acid molecule comprising a 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO:3, the sequence of SEQ ID NO:3, the sequence of SEQ ID NO:3, the sequence of SEQ ID
- the invention relates to a nucleic acid molecule which is complementary to the nucleic acid molecule as described herein above.
- This embodiment of the invention comprising at least 14 nucleotides and covering at least position -13910 or position -22018 of the sequence upstream of the LPH gene is particularly useful in the analysis of the genetic setup in the recited positions in hybridization assays.
- a 15mer exactly complementary either to the wild-type sequence i.e. a T in position -13910 or an A in position -22018
- to the variants contributing to or indicative of adult-type hypolactasia i.e. a C in position -13910 or a G in position -22018
- a nucleic acid molecule labeled with a detectable label not exactly complementary to the DNA in the analyzed sample will not give rise to a detectable signal, if appropriate hybridization and washing conditions are chosen.
- the invention relates to a vector comprising the nucleic acid molecule as described herein above.
- the vector of the invention may either contain a nucleic acid molecule comprising the wild-type sequence(s) or it may contain a nucleic acid molecule comprising the mutant sequence(s).
- suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDVI (Pharmacia), pCDM8, pRc/CMV, pcDNAI, pcDNA3, the EchoTM Cloning System (Invitrogen), pSPORTI (GIBCO BRL) or pRevTet-On/pRevTet-Off or pCI (Promega).
- the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used.
- the invention relates to a non-human host transformed with the vector of the invention as described herein above.
- the host may either carry the mutant or the wild-type sequence.
- the host may be heterozygous or homozygous for one or both SNPs.
- the wild-type nucleic acid molecule referred to above and contained in the pharmaceutical composition of the invention may be combined with a pharmaceutically acceptable carrier and/or diluent.
- suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
- Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration.
- Said restriction enzymes which cut rg/cy where found by the use of the program Webcutter.
- the analysis of the digestion product can be effected by conventional means, such as by gel electrophoresis which may be optionally combined by the staining of the nucleic acid with, for example, ethidium bromide. Combinations with further techniques such as Southern blotting are also envisaged.
- amplification is effected by polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- Other amplification methods such as ligase chain reaction may also be employed.
- said nucleic acid molecule from said sample is fixed to a solid support.
- Fixation of the nucleic acid molecule to a solid support will allow an easy handling of the test assay and furthermore, at least some solid supports such as chips, silica wafers or microtiter plates allow for the simultaneous analysis of larger numbers of samples.
- the solid support allows for an automated testing employing, for example, roboting devices.
- Fig. 7 The sequence of the lactase persisting-type intron 9 of the MCM6 gene(1295bp) comprising at position -22018 an A. Said position is indicated by the use of a small letter. This sequence refers to SEQ ID NO:4.
- the family material consisted of nine extended Finnish pedigrees originally studied by Sahi 5 . All family material was tested for adult-type hypolactasia in the 1970s. The family material for this study was enlarged by collecting the DNA of the family members in the younger generations. The family material in this study consisted of 194 individuals in total (Fig. 1). The phenotypic status of all family members was confirmed by lactose tolerance tests with ethanol (LTTE) 4"5 in all but 49 individuals. Gluten enteropathy has been excluded in all affected patients by measurement of the serum IgA anti-tissue transglutaminase 45 . DNA was extracted from blood samples taken from all participating family members in accordance with standard protocols 46 , after obtaining informed consent.
- CTACCCTATCAGTAAAGGCCTA-3' were used under conditions described above.
- 10 ⁇ l of the PCR product was captured in a streptavidin coated microtiter well (Lab systems, Finland). The wells were washed, and bound DNA was denaturated as described by Syvanen et al. (Am J Hum Genet. (1993), 52, 46-59) and Syvanen and Landegren (Hum Mutat. (1994), 3, 172-9).
- 50 ⁇ of the minisequencing reaction mixture contained 10 pmoles of the minisequencing primers for C/T. 13 9 1 5 (5'-
- Bio-Reverse primer BIO-TGCTCAGGACATGCTGATCAA Tm 62 SEQ ID NO: 13 or Bio-TTGATCAGCATGTCCTGAGCA SEQ ID NO: 11
- Lactase non-persistence 0 144 Lactase persistence 187 a non-Finnish samples consist of 23 South Korean, 9 Italian and 7 German individuals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a nucleic acid molecule comprising a 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene contributing to or indicative of the adult-type hypolactasia wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, the sequence of SEQ ID NO:1 is also depicted in the Fig. 4 and comprised in the sequence as depicted in the Fig. 8; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 2, the sequence of SEQ ID NO:2 is also depicted in Fig.5 and comprised in the sequence as depicted in the Fig. 9; (c) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 5' from the LPH gene a cytosine residue; and (d) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 5' from the LPH gene a guanine residue. The present invention further relates to methods for testing for the presence of or predisposition to adult-type hypolactasia that are based on the analysis of an SNP contained in the above recited nucleic acid molecule. Additionally, the present invention relates to diagnostic composition and kit useful in the detection of the presence of or predisposition to adult-type hypolactasia.
Description
Identification of a DNA variant associated with adult type hypolactasia
The present invention relates to a nucleic acid molecule comprising a 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene contributing to or indicative of the adult-type hypolactasia wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, the sequence of SEQ ID NO:1 is also depicted in Fig. 4 and comprised in the sequence as depicted in Fig. 8; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 2, the sequence of SEQ ID NO:2 is also depicted in Fig. 5 and comprised in the sequence as depicted in Fig. 9; (c) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 5' from the LPH gene a cytosine residue; and (d) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 5' from the LPH gene a guanine residue. The present invention further relates to methods for testing for the presence of or predisposition to adult- type hypolactasia that are based on the analysis of an SNP contained in the above recited nucleic acid molecule. Additionally, the present invention relates to diagnostic composition and kit useful in the detection of the presence of or predisposition to adult-type hypolactasia.
A variety of documents is cited throughout this specification. The disclosure content' of these documents, including manufacturer's manuals and catalogues, is herewith" incorporated by reference.
Lactase-phlorizin hydrolase enzyme (LPH), which is exclusively expressed by intestinal epithelial cells, hydrolyses lactose, sugar of milk, into glucose and galactose1. The expression of the LPH enzyme dramatically declines to very low
levels at the weaning period in mammals when lactose is no longer an essential part of the diet. In humans, the condition known as adult-type hypolactasia or lactase non- persistence, affects most populations and severely limits the use of fresh milk among adults due to lactose intolerance. The age of onset of lactase non-persistence status varies between populations, ranging from 1-2 years of age among the Thais to 10-20 years of age among the Finns2"3. However, in Northern European and a few other ethnic groups, LPH activity persists throughout life in the majority of adults, a condition known as lactase persistence. The phenotype lactase persistence/non- persistence has been shown to be genetically determined, the persistent status being dominant over the non-persistent status4"6.
The state of the art diagnosis of adult-type hypolactasia is based on the lactose tolerance test (LTT). After overnight fasting (10 hours), 1g/kg of lactose is given as a 12.5% solution, the maximum dose being 50g. Capillary blood samples are taken before and 20 and 30 min after lactose ingestion. The glucose concentration is determined by the glucose oxidase method (Hjelm and de Verdier 1963). Abdominal symptoms on the day of LTT are noted. A maximum rise in blood glucose concentration of 1.1 mmol/l or more was taken as a sign of lactose malabsorption (Gudman-Hoyer and Harnum 1968, Jussila 1970, Sahi 1972). LTT contains a 10% risk for false positive and negative diagnoses, i.e. the sensitivity and specificity of LTT is about 90% (Isokoski et al. 1972, Newcomer et al. 1975, Sahi 1983). The accuracy of LTT can be improved by giving 0.3 g/kg ethanol that inhibits the metabolism of galactose in the liver (Tygstrup and Lundqvist 1962) and 15 min later 1g/kg lactose as 12.5% solution.
Children with maximum rises of less than 0.2mg/100ml in the first or repeated LTT have been sent for small-intestinal biopsy that is taken through gastroscopy. This is an invasive procedure that needs expertise and is usually performed at university hospitals by specialists in gastroenterology only. Biopsy samples are examined with a dissection microscope and histologically, and the mucosal maltase, sucrase and lactase activities are determined (Launiala et al. 1964). The diagnosis of hypolactasia in children is justified if the histology of the intestinal biopsy is normal and lactase activity is less than 20U/g protein and lactase/sucrase ratio less than 0.30, or in the
LTT with ethanol administration a maximum rise in blood glucose concentration of less than 20mg/100ml and in galactose concentration of 5mg/100 ml or less (Sahi et al, 1972) is demonstrated. As described above, the current methods to diagnose adult-type hypolactasia are laborious. LTT is inexact and therefore, an invasive procedure, gastroscopy is needed before the diagnosis can be ascertained. Since adult-type hypolactasia is very common and the major cause of nonspecific abdominal symptoms (in one third of patients complaining stomach pain), there is a clear need to improve the diagnostics of this common health problem.
Yet, so far no biochemical test that is easy to handle and, at the same time, provides quick and accurate results has been developed. Elucidation of the cause of the disease on the genomic DNA/ expression level has equally been unsuccessful. Thus, the sequencing of the coding and promoter regions of the LPH gene in adults has revealed no DNA-variations which correlate with lactase persistence/ non- persistence, nor has evidence emerged of splice variants or mRNA editing variants associated with this trait7"8. Previous studies have shown that the lactase persistence/non-persistence trait is possibly controlled by cis-acting element(s) residing within or adjacent to the lactase gene, and strong linkage disequilibrium (LD) has been observed across the 70 kb haplotype spanning the lactase gene9,10. Several studies report evidence that the main control of the LPH gene expression operates at the level of transcription regulation11"13. However, it has been suggested that variation influencing both transcriptional and posttranscriptional control of expression of the LPH gene may be involved in the etiology of adult-type hypolactasia14"15.
In view of the above, the technical problem underlying the present invention was to provide means and methods that allow for an accurate and convenient diagnosis of adult-type hypolactasia or of a predisposition to this disease.
The solution to said technical problem is achieved by the embodiments characterized in the claims.
Thus, the present invention relates to a nucleic acid molecule comprising a 5' portion
of an intestinal lactase-phlorizine hydrolase (LPH) gene contributing to or indicative of adult-type hypolactasia wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, the sequence of SEQ ID NO:1 is also depicted in Fig. 4 and comprised in the sequence as depicted in Fig. 8; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 2, the sequence of SEQ ID NO:2 is also as depicted in Fig. 5 and comprised in the sequence as depicted in Fig. 9; (c) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 5' from the LPH gene a cytosine residue; and (d) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 5' from the LPH gene a guanine residue.
In accordance with the invention, the term "intestinal lactase-phlorizine hydrolase (LPH) gene" denotes a gene that encodes an enzyme having the activity of hydrolyzing lactose into its components glucose and galactose. The enzyme is characterized by E.G. 3.2.1.23.62.
The term "adult-type hypolactasia" refers to a condition also known as lactose intolerance, which is an autosomal recessive condition resulting from the "physiological" decline of the lactase-phlorizin hydrolase (LPH) enzyme activity in intestinal cells in a significant proportion of the global population.
The term "contributing to or indicative of adult-type hypolactasia", refers to the fact that the SNPs and thus the corresponding nucleic acid molecules found are indicative of the condition and possibly also causative therefore. Accordingly, this term necessarily requires that the recited 5' position is indicative of the condition. Said term, on the other hand, does not necessarily requite that the 5' portion is causative or contributes to the condition. Yet, said term does not exclude a causative or contributory role of either or both SNPs.
The term "which hybridizes under stringent conditions" refers to hybridization conditions that are well known to or can be established by the person skilled in the art according to conventional protocols. The term most advantageously refers to highly stringent conditions. Appropriate stringent conditions for each sequence may be established on the basis of well-known parameters such as temperature, composition of the nucleic acid molecules, salt conditions etc.: see, for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual"; CSH Press, Cold Spring Harbor, 1989 or Higgins and Hames (eds.), "Nucleic acid hybridization, a practical approach", IRL Press, Oxford 1985 (reference 54), see in particular the chapter "Hybridization Strategy" by Britten & Davidson, 3 to 15. Typical (highly stringent) conditions comprise hybridization at 65°C in O.δxSSC and 0.1% SDS or hybridization at 42°C in 50% formamide, 4xSSC and 0.1% SDS. Hybridization is usually followed by washing to remove unspecific signal. Washing conditions include conditions such as 65°C, 0.2xSSC and 0.1% SDS or 2xSSC and 0,1% SDS or 0,3XSSC and 0,1% SDS at 25°C - 65°C.
As disclosed herein above, the present invention also relates to a hybridizing nucleic acid molecules of at least 20 nucleotides; see (c) and (d) herein above. Yet, the present invention also relates to a nucleic acid molecule of at least 50, at least 100, at least 150, or at least 200 nucleotides. Preferably, said hybridizing fragments comprise at least 25, at least 50, or at least 75 nucleotides, at least 100 nucleotides, 5' and 3' of the position -13910 as defined in (c) or of position -22018 ad defined in (d) herein above.
The term "nucleic acid molecule" refers both to naturally and non-naturally occurring nucleic acid molecules. Non-naturally occurring nucleic acid molecules include cDNA as well as derivatives such as PNA.
The term "nucleic acid molecule [...] comprising the nucleic acid sequence of SEQ ID NO:" throughout this specification refers to nucleic acid molecules that are at least 1 nucleotide longer than the nucleic acid molecule specified by the SEQ ID NO. At the same time, these nucleic acid molecules extend, at a maximum, 30000 nucleotides
over the 5' and/or 3' end of the nucleic acid molecule of the invention specified e.g. by the SEQ ID NO: 2 or 1. 3 or 4.
Surprisingly, it was found in accordance with the present invention that the two hypolactasia-associated variants locate at a considerable distance from the LPH gene, positioned in different introns of the MCM6 gene. MCM6 is a member of a gene family (MCM 2-7), required for the initiation of DNA replication ensuring that it takes place only once during the cell cycle31. MCM6, unlike LPH, is not restricted in its tissue distribution and there is no correlation in the levels of MCM6 and LPH transcripts18. These findings would suggest that these two genes do not share any functionally significant cis-acting elements providing tissue specificity or developmental regulation18. Most probably the identified variants have different functional significance for the expression of the LPH and MCM6 genes. Further surprisingly, based on complete association to hypolactasia they (or one of them) are associated to age-dependent down regulation of the transcript level of the LPH gene in the intestinal epithelium but have little or no effect on the transcription of the MCM6.
Experimentally, using linkage, allelic association and extended haplotype analysis carried out in nine extended Finnish families the adult-type hypolactasia locus was restricted to a 47 kb interval on 2q21. The sequence analysis of the region revealed a single nucleotide polymorphism (SNP), C/T-13910 that completely cosegregated with adult-type hypolactasia in all Finnish families and in a sample set of 236 individuals from four different populations. Another SNP G/A-22018 residing 8 kb telomeric from C/T -13910 was associated with the trait in all but 7 cases. The prevalence of C/T - 13910 SNP in 1047 DNA samples reflected the reported prevalence of adult-type hypolactasia in three different populations providing additional evidence for its importance for the trait.
The surprising finding referred to above for the first time allows the establishment of test systems that are based on the molecular analysis of the recited single nucleotide polymorphisms upstream of the LPH gene. Whereas both SNPs provide for a solid basis for the diagnosis of or the diagnosis of a predisposition to adult-type
hypolactasia, it is preferred that the nucleotide position -13910 is analyzed, either alone or in combination with nucleotide position -22018. This is because the SNP at position -13910 was associated in 100% of the analysed cases with the disease whereas the SNP at position -22018 was associated in only 98% of all cases with adult-type hypolactasia. Nevertheless, analyses of nucleotide position -22018 alone will usually also provide a sound basis for a diagnosis of a predisposition to adult- type hypolactasia.
Due to the abundance of established methods for assessing for the presence of SNPs, it is now possible to conveniently, in a short amount of time, at low cost, with high accuracy and without significant trouble for the person under investigation, diagnose a genetic predisposition to adult-type hypolactasia.
The invention further relates to a nucleic acid molecule comprising a 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO:3, the sequence of SEQ ID
NO:3 is also depicted in Fig. 6; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO:4, the sequence of SEQ ID NO:4 is also depicted in Fig. 7; (c) a nucleic acid molecule the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 of the LPH gene a thymidine residue; and (d) a nucleic acid molecule the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 of the LPH gene a adenosine residue.
This embodiment of the present invention may conveniently be used to demonstrate that a person does not suffer from adult-type hypolactasia and has no predisposition therefor. Further, this nucleic acid molecule reflecting the "wild-type" situation of the position -13910 or -22018 upstream of the LPH gene may be used as a control means in experiments where a predisposition to adult-type hypolactasia is tested for.
For testing, methods as described throughout this specification may be used.
In a preferred embodiment of the invention the nucleic acid molecule is genomic DNA. This preferred embodiment of the invention reflects the fact that usually the analysis would be carried out on the basis of genomic DNA from body fluid, cells or tissue isolated from the person under investigation.
In a further preferred embodiment of the nucleic acid molecule of the invention said genomic DNA is part of a gene.
In accordance with the invention, it is preferred that at least one of the introns of the MCM6 gene harboring position -13910 or position -22018 relative to the LPH gene is analyzed.
In addition, the invention relates to a fragment of the nucleic acid molecule as described herein above having at least 14 nucleotides wherein said fragment comprises nucleotide position -13910 or nucleotide position -22018 (upstream) of the LPH gene. The fragment of the invention may be of natural as well as of (semi)synthetic origin. Thus, the fragment may, for example, be a nucleic acid molecule that has been synthesized according to conventional protocols of organic chemistry. Importantly, the nucleic acid fragment of the invention comprises nucleotide position -13910 or nucleotide position -22018 upstream of the LPH gene. In these positions, the fragment may have either the wild-type nucleotide or the nucleotide contributing to or indicative of adult-type hypolactasia (also referred to as the "mutant" sequence). Consequently, the fragment of the invention may be used, for example, in assays differentiating between the wild-type and the mutant sequence. It is further preferred that the fragment of the invention consists of at least 17 nucleotides, more preferred at least 21 nucleotides, and most preferred at least 25 nucleotides such as 30 nucleotides.
Furthermore, the invention relates to a nucleic acid molecule which is complementary to the nucleic acid molecule as described herein above.
This embodiment of the invention comprising at least 14 nucleotides and covering at least position -13910 or position -22018 of the sequence upstream of the LPH gene is particularly useful in the analysis of the genetic setup in the recited positions in hybridization assays. Thus, for example, a 15mer exactly complementary either to the wild-type sequence (i.e. a T in position -13910 or an A in position -22018) or to the variants contributing to or indicative of adult-type hypolactasia (i.e. a C in position -13910 or a G in position -22018) may be used to differentiate between the polymorphic variants. This is because a nucleic acid molecule labeled with a detectable label not exactly complementary to the DNA in the analyzed sample will not give rise to a detectable signal, if appropriate hybridization and washing conditions are chosen.
In this regard, it is important to note that the nucleic acid molecule of the invention, the fragment thereof as well as the complementary nucleic acid molecule may be detectably labeled. Detectable labels include radioactive labels such as 3H, or 32P or fluorescent labels. Labeling of nucleic acids is well understood in the art and described, for example, in Sambrook et al., loc. cit.
In addition, the invention relates to a vector comprising the nucleic acid molecule as described herein above. The vector of the invention may either contain a nucleic acid molecule comprising the wild-type sequence(s) or it may contain a nucleic acid molecule comprising the mutant sequence(s).
The vectors may particularly be plasmids, cosmids, viruses or bacteriophages used conventionally in genetic engineering that comprise the nucleic acid molecule of the invention. Preferably, said vector is an expression vector and/or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the nucleic acid molecule of the invention into targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook et al., loc. cit. and Ausubel et al., Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989). Alternatively, the nucleic acid molecules and vectors of the invention can be reconstituted into
liposomes for delivery to target cells. The vectors containing the nucleic acid molecules of the invention can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas, e.g., calcium phosphate or DEAE-Dextran mediated transfection or electroporation may be used for other cellular hosts; see Sambrook, supra.
Such vectors may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions. Preferably, the nucleic acid molecule of the invention is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells. Expression of said polynucleotide comprises transcription of the polynucleotide into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian ceils, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and, optionally, a poly-A signal ensuring termination of transcription and stabilization of the transcript, and/or an intron further enhancing expression of said polynucleotide. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally-associated or heterologous promoter regions. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the PL, lac, trp or tac promoter in E. coli, and examples for regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40- , RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk- poly-A site, downstream of the polynucleotide. Optionally, the heterologous sequence can encode a fusion protein including an C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDVI (Pharmacia), pCDM8, pRc/CMV, pcDNAI, pcDNA3, the Echo™ Cloning System (Invitrogen), pSPORTI (GIBCO BRL) or pRevTet-On/pRevTet-Off or pCI (Promega). Preferably, the expression control sequences will be eukaryotic promoter systems in
vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used.
As mentioned above, the vector of the present invention may also be a gene transfer or targeting vector. Gene therapy, which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Suitable vectors and methods for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911- 919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Wang, Nature Medicine 2 (1996), 714- 716; W094/29469; WO 97/00957, Schaper, Current Opinion in Biotechnology 7 (1996), 635-640, or Kay et al. (2001) Nature Medicine, 7, 33-40) and references cited therein. The polynucleotides and vectors of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) into the cell. Preferably, said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom, most preferably said cell is a stem cell. Gene therapy is envisaged with the wild-type nucleic acid molecule only.
The invention as well relates to a primer or primer pair, wherein the primer or primer pair hybridizes under (highly) stringent conditions to the nucleic acid as described herein above comprising nucleotide position -13910 or -22018 of the LPH gene or to the complementary strand thereof.
Preferably, the primers of the invention have a length of at least 14 nucleotides such as 17 or 21 nucleotides. It is further preferred that the primers have a maximum length of 24 nucleotides. Hybridization or lack of hybridization of a primer under appropriate conditions to a genome sequence comprising either position -13910 or position -22018 coupled with an appropriate detection method such as an elongation reaction or an amplification reaction may be used to differentiate between the polymorphic variants and then draw conclusions with regard to, e.g., the predisposition of the person under investigation for adult-type hypolactasia. The present invention envisages two types of primers/primer pairs. One type hybridizes to a sequence comprising the mutant sequence. In other words, the primer is exactly complementary to a sequence that contains the C in position -13910 or the G in
position -22018 or to the complementary strand thereof. The other type of primer is exactly complementary to a sequence having a T in position -13910 or an A in position -22018 or to the complementary strand thereof. Since hybridization conditions would preferably be chosen to be stringent enough, contacting of e.g. a primer exactly complementary to the mutant sequence with a wild-type allele would not result in efficient hybridization due to the mismatch formation. After washing, no signal would be detected due to the removal of the primer.
Additionally, the invention relates to a non-human host transformed with the vector of the invention as described herein above. The host may either carry the mutant or the wild-type sequence. Upon breeding etc. the host may be heterozygous or homozygous for one or both SNPs.
The host of the invention may carry the vector of the invention either transiently or stably integrated into the genome. Methods for generating the non-human host of the invention are well known in the art. For example, conventional transfection protocols described in Sambrook et al., loc. cit., may be employed to generate transformed bacteria (such as E. coii) or transformed yeasts. The non-human host of the invention may be used, for example, to elucidate the onset of adult-type hypolactasia.
In a preferred embodiment of the invention the non-human host is a bacterium, a yeast cell, an insect cell, a fungal cell, a mammalian cell, a plant cell, a transgenic animal or a transgenic plant.
Whereas E. coli is a preferred bacterium, preferred yeast cells are S. cerevisiae or Pichia pastoris cells. Preferred fungal cells are Aspergillus cells and preferred insect cells include Spodoptera frugiperda cells. Preferred mammalian cells are colon carcinoma cell lines showing expression of the LPH enzyme and include CaCo2- cells.
A method for the production of a transgenic non-human animal, for example transgenic mouse, comprises introduction of the aforementioned polynucleotide or targeting vector into a germ cell, an embryonic cell, stem cell or an egg or a cell derived therefrom. The non-human animal can be used in accordance with a screening method of the invention described herein. Production of transgenic
embryos and screening of those can be performed, e.g., as described by A. L. Joyner Ed., Gene Targeting, A Practical Approach (1993), Oxford University Press. The DNA of the embryonal membranes of embryos can be analyzed using, e.g., Southern blots with an appropriate complementary nucleic acid molecule; see supra. A general method for making transgenic non-human animals is described in the art, see for example WO 94/24274. For making transgenic non-human organisms (which include homologously targeted non-human animals), embryonal stem cells (ES cells) are preferred. Murine ES cells, such as AB-1 line grown on mitotically inactive SNL76/7 cell feeder layers (McMahon and Bradley, Cell 62:1073-1085 (1990)) essentially as described (Robertson, E. J. (1987) in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E. J. Robertson, ed. (Oxford: IRL Press), p. 71-112) may be used for homologous gene targeting. Other suitable ES lines include, but are not limited to, the E14 line (Hooper et al., Nature 326:292-295 (1987)), the D3 line (Doetschman et al., J. Embryol. Exp. Morph. 87:27-45 (1985)), the CCE line (Robertson et al., Nature 323:445-448 (1986)), the AK-7 line (Zhuang et al., Cell 77:875-884 (1994)). The success of generating a mouse line from ES cells bearing a specific targeted mutation depends on the pluripotence of the ES cells (i. e., their ability, once injected into a host developing embryo, such as a blastocyst or morula, to participate in embryogenesis and contribute to the germ cells of the resulting animal). The blastocysts containing the injected ES cells are allowed to develop in the uteri of pseudopregnant nonhuman females and are born as chimeric mice. The resultant transgenic mice are chimeric for cells having the desired nucleic acid molecule are backcrossed and screened for the presence of the correctly targeted transgene (s) by PCR or Southern blot analysis on tail biopsy DNA of offspring so as to identify transgenic mice heterozygous for the nucleic acid molecule of the invention.
The transgenic non-human animals may, for example, be transgenic mice, rats, hamsters, dogs, monkeys (apes), rabbits, pigs, or cows. Preferably, said transgenic non-human animal is a mouse. The transgenic animals of the invention are, inter alia, useful to study the phenotypic expression/outcome of the nucleic acids and vectors of the present invention. Furthermore, the transgenic animals of the present invention are useful to study the developmental expression of the LPH enzyme, for example in
the rodent intestine. It is furthermore envisaged, that the non-human transgenic animals of the invention can be employed to test for therapeutic agents/compositions or other possible therapies which are useful to ameliorate adult-type hypolactasia.
In addition, the invention relates to an antibody or aptamer or phage that specifically binds to the mutant nucleic acid molecule of the invention but not to the corresponding wild type nucleic acid molecule.
The antibody may be tested for binding and used in any serologic technique well known in the art, such as agglutination techniques in tubes, gels, solid phase and capture techniques with or without secondary antibodies, or in flow cytometry with or without immunofluorescence enhancement (see, for example, techniques described in Harlow and Lane ..Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, USA, 1988 (see reference 53).
In line with the invention, the antibody specifically recognizes an epitope comprising position -13910 (wherein the nucleotide is C) or position -22018 (wherein the nucleotide is G). It does not or essentially does not cross-react with an epitope comprising position -13910 with a T in this position nor with the epitope comprising position -22018 with a G in this position. Specificity of an antibody which may be generated according to standard protocols, may be tested by contacting with DNA molecules carrying the wild-type and the mutant sequence such as in an ELISA assay. Only those antibodies will be selected that produce a signal over background with the mutant sequence but not with the wild-type sequence.
The antibody of the invention may be a monoclonal antibody or an antibody derived from or comprised in a polyclonal antiserum. The term "antibody", as used in accordance with the present invention, further comprises fragments of said antibody such as Fab, F(ab')2, Fv or scFv fragments; see, for example, Harlow and Lane53, loc. cit. The antibody or the fragment thereof may be of natural origin or may be (semi)synthetically produced. Such synthetic products also comprise non- proteinaceous as semi-proteinaceous material that has the same or essentially the same binding specificity as the antibody of the invention. Such products may, for example, be obtained by peptidomimetics.
The term "aptamer" is well known in the art and defined, e.g., in Osborne et al., Curr. Opin. Chem. Biol. I (1997), 5-9 (see reference 51) or in Stall and Szoka, Pharm. Res. 12 (1995), 465-483 (see reference 52).
Moreover, the invention relates to an antibody or aptamer or phage that specifically binds to the wild-type nucleic acid molecule as described herein above but not to the corresponding mutant sequence contributing to or indicative of adult-type hypolactasia. The statements with respect to specificity etc. made for the antibody which is specific for the mutant sequence apply mutatis mutandis here.
Furthermore, the invention relates to a pharmaceutical composition comprising the wild-type nucleic acid molecule as described herein above.
The pharmaceutical composition of the invention may be used in gene therapy approaches, particularly in somatic gene therapy.
The wild-type nucleic acid molecule referred to above and contained in the pharmaceutical composition of the invention may be combined with a pharmaceutically acceptable carrier and/or diluent. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. A typical dose can be, for example, in the range of 0.001 to 1000 μg of nucleic acid for expression or for inhibition of expression; however, doses below or above this exemplary range are envisioned, especially considering the
aforementioned factors. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 106 to 1012 copies of the DNA molecule. Progress can be monitored by periodic assessment. The compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
Additionally, the invention relates to a diagnostic composition comprising the nucleic acid molecule as described herein above, the vector as described herein above, the primer or primer pair as described herein above, and/or the antibody aptamer and/or phage as described herein above.
The diagnostic composition is useful for assessing the genetic status of a person with respect to his or her predisposition to develop adult-type hypolactasia or with regard to the diagnosis of the acute condition. The various possible components of the diagnostic composition may be packaged in one or more vials, in a solvent or otherwise such as in lyophilized form. If dissolved in a solvent, the diagnostic composition is preferably cooled to at least +8°C to +4°C. Freezing may be preferred in other instances.
The invention also relates to a method for testing for the presence or predisposition of adult-type hypolactasia or associated trait comprising testing a sample obtained from a prospective patient or from a person suspected of carrying such a
predisposition to the presence of the nucleic acid molecule as described herein above in a homozygous or heterozygous state. In varying embodiments, it may be tested either for the presence of the wild-type sequence(s) or of the mutant sequence(s).
The method of the invention is useful for detecting the genetic set-up of said person/patient and drawing appropriate conclusions whether a condition from which said patient suffers is adult-type hypolactasia. Alternatively, it may be assessed whether a person not suffering from a condition carries a predisposition to adult-type hypolactasia. With regard to position -13910 upstream of the LPH gene, only if cytosine is found in a homozygous state, a condition would be diagnosed as adult- type hypolactasia or a corresponding predisposition would be manifest. On the other hand, if thymidine is found in a homozygous state or if the individual is heterozygous (C/T), then it may be concluded that a condition from which a patient suffers is not related to adult-type hypolactasia and further, that the patient does not carry a predisposition to develop this condition. It may, however, be concluded that children of persons carrying the heterozygous genotype may develop the condition if chromosome carrying the C residue is matched with a corresponding chromosome from the other parent.
The situation is similar and essentially the same conclusions apply for the analysis of the SNP in position -22018. A homozygously occurring G residue marks a predisposition to or the occurrence of acute adult-type hypolactasia. A heterzygous G/A state correlates with a high likelihood to not develop the condition. Individuals carrying A in a homozygous state would not be expected to develop the condition. Similarly, patients suffering from a condition would be diagnosed not to suffer from adult-type hypolactasia.
In a preferred embodiment of the method of the invention said testing comprises hybridizing the complementary nucleic acid molecule as described herein above which is complementary to the nucleic acid molecule contributing to or indicative of adult-type hypolactasia or the nucleic acid molecule as described herein above which is complementary to the wild-type sequence as a probe under (highly) stringent
conditions to nucleic acid molecules comprised in said sample and detecting said hybridization.
Again, depending on the nucleic acid probe used, either wild-type or mutant sequences (i.e. sequences contributing to or indicative of adult-type hypolactasia) would be detected. It is understood that hybridization conditions would be chosen such that a nucleic acid molecule complementary to wild-type sequences would not or essentially not hybridize to the mutant sequence. Similarly, a nucleic acid molecule complimentary to the mutant sequence would not or would not essentially not hybridize to the wild-type sequence. In order to differentiate between results obtained from homozygous and heterozygous genotypes in the hybridization methods of the invention, one can for example monitor/detect the strength/intensity of the respective detection signal after the hybridization. To differentiate between wild-type homozygous, heterozygous and/or mutant homozygous allels in the hybridization methods of the invention, internal control samples of the corresponding genotypes will be included in the analysis.
In a further preferred embodiment, the method of the invention further comprises digesting the product of said hybridization with a restriction endonuclease or subjecting the product of said hybridization to digestion with a restriction endonuclease and analyzing the product of said digestion.
This preferred embodiment of the invention allows by convenient means, the differentiation between an effective hybridization and a non-effective hybridization. For example, if the DNA sequence adjacent to position -13910 or position -22018 comprises an endonuclease restriction site, the hybridized product will be cleavable by an appropriate restriction enzyme upon an effective hybridization whereas a lack of hybridization will yield no double-stranded product or will not comprise the recognizable restriction site and, accordingly, will not be cleaved. In particular, the restriction enzymes specific for the sequence of the DNA-variant C/T-139io is CviJ I, for the DNA-variant G/A.22ois are Hhal and Aci I. Said restriction enzymes which cut rg/cy where found by the use of the program Webcutter. The analysis of the digestion product can be effected by conventional means, such as by gel electrophoresis which may be optionally combined by the staining of the nucleic acid with, for example, ethidium bromide. Combinations with further techniques such as Southern
blotting are also envisaged.
Detection of said hybridization may be effected, for example, by an anti-DNA double- strand antibody or by employing a labeled oligonucleotide. Conveniently, the method of the invention is employed together with blotting techniques such as Southern or Northern blotting and related techniques. Labeling may be effected, for example, by standard protocols and includes labeling with radioactive markers, fluorescent, phosphorescent, chemiluminescent, enzymatic labels, etc. (see also above).
In accordance with the above, in another preferred embodiment of the method of the invention said probe is detectably labeled, e.g. by the methods and with the labels described herein above.
In yet another preferred embodiment of the method of the invention said testing comprises determining the nucleic acid sequence of at least a portion of the nucleic acid molecule as described herein above, said portion comprising nucleotide position
-13910 and/or nucleotide position -22018 of the LPH gene.
Determination of the nucleic acid molecule may be effected in accordance with one of the conventional protocols such as the Sanger or Maxam/Gilbert protocols (see Sambrook et al., loc. cit., for further guidance).
In a further preferred embodiment of the method of the invention the determination of the nucleic acid sequence is effected by solid-phase minisequencing. Solid-phase minisequencing is based on quantitative analysis of the wild type and mutant nucleotide in a solution. First, the genomic region containing the mutation is amplified by PCR with one biotinylated and non-biotinylated primer where the biotinylated primer is attached to a streptavidin (SA) coated plate. The PCR-product is denatured to a single stranded form to allow a minisequencing primer to bind to this strand just before the site of the mutation. The tritium (H3) or fluorescence labeled mutated and wild type nucleotides together with nonlabeled dNTPs are added to the minisequencing reaction and sequenced using Taq-polymerase. The result is based on the amount of wild type and mutant nucleotides in the reaction measured by beta counter or fluorometer and expressed as an R-ratio. See also Syvanen AC, Sajantila
A, Lukka M. Am J Hum Genet 1993: 52,46-59 and Suomalainen A and Syvanen AC. Methods Mol Biol 1996;65:73-79.
A preferred embodiment of the method of the invention further comprises, prior to determining said nucleic acid sequence, amplification of at least said portion of said nucleic acid molecule.
Preferably, amplification is effected by polymerase chain reaction (PCR). Other amplification methods such as ligase chain reaction may also be employed.
In a preferred embodiment of the method of the invention said testing comprises carrying out an amplification reaction wherein at least one of the primers employed in said amplification reaction is the primer as described herein above or belongs to the primer pair as described herein above, comprising assaying for an amplification product. In this embodiment and depending on the information the investigator/physician wishes to obtain, primers hybridizing either to the wild-type or mutant sequences may be employed.
The method of the invention will result in an amplification of only the target sequence, if said target sequence carries a sequence exactly complementary to the primer used for hybridization. This is because the oligonucleotide primer will under preferably (highly) stringent hybridization conditions not hybridize to the wild-type/mutant sequence - depending which type of primer is used - (with the consequence that no amplification product is obtained) but only to the exactly matching sequence. Naturally, combinations of primer pairs hybridizing to both SNPs may be used. In this case, the analysis of the amplification products expected (which may be no, one, two, three or four amplification product(s) if the second, non-differentiating primer is the same for each locus) will provide information on the genetic status of both positions - 13910 and -22018.
In a preferred embodiment of the method of the invention said amplification is effected by or said amplification is the polymerase chain reaction (PCR).
The PCR is well established in the art. Typical conditions to be used in accordance with the present invention include for example a total of 35 cycles in a total of 50 /I volume exemplified with a denaturation step at 93° C for 3 minutes; an annealing
step at 55° C for 30 seconds; an extension step at 72° C for 75 seconds and a final extension step at 72° C for 10 minutes.
The invention furthermore relates to a method for testing for the presence or predisposition of adult-type hypolactasia comprising assaying a sample obtained from a human for specific binding to the antibody or aptamer or phage as described herein above. In this context a weaker staining for the presence of the antigen of the invention compared to homozygous wild type control samples (comprising two persistent allels) is indicative for the heterozygous wild type (one persistent allele and one hypolactasic allele, whereas for the homozygous hypolactasic individual no staining is expected if the appropriate antibody is used. Preferably, the method of the invention is performed in the presence of control samples corresponding to all three possible allelic combinations as internal controls. Testing may be carried out with an antibody etc. specific for the wild-type or specific for the mutant sequence. Testing for binding may, again, involve the employment of standard techniques such as ELISAs; see, for example, Harlow and Lane53, loc. cit.
In a preferred embodiment of the method of the invention said antibody or aptamer or phage is detectably labeled. Whereas the aptamers are preferably radioactively labeled with 3H or 32P or with a fluorescent marker as described above, the phage or antibody may either be labeled in a corresponding manner (with 131l as the preferred radioactive label) or be labeled with a tag such as His-tag, FLAG-tag or myc-tag.
In a further preferred embodiment of the method of the invention the test is an immuno-assay.
In another preferred embodiment of the method of the invention said sample is blood, serum, plasma, fetal tissue, saliva, urine, mucosal tissue, mucus, vaginal tissue, fetal tissue obtained from the vagina, skin, hair, hair follicle or another human tissue.
In an additional preferred embodiment of the method of the invention said nucleic acid molecule from said sample is fixed to a solid support.
Fixation of the nucleic acid molecule to a solid support will allow an easy handling of the test assay and furthermore, at least some solid supports such as chips, silica wafers or microtiter plates allow for the simultaneous analysis of larger numbers of samples. Ideally, the solid support allows for an automated testing employing, for example, roboting devices.
In a particularly preferred embodiment of the method of the invention said solid support is a chip, a silica wafer, a bead or a microtiter plate.
Furthermore, the invention relates to the use of the nucleic acid molecule as described herein above for the analysis of the presence or predisposition of adult- type hypolactasia.
The nucleic acid molecule simultaneously allows for the analysis of the absence of the condition or the predisposition to the condition, as has been described in detail herein above.
In addition, the invention relates to a kit comprising the nucleic acid molecule as described herein above, the primer or primer pair as described herein above, the vector as described herein above, and/or the antibody aptamer and/or phage as described herein above in one or more containers.
The invention as well relates to the use of the nucleic acid molecule as described herein above or the vector as described herein above in gene therapy.
Gene therapy approaches have been discussed herein above in connection with the vector of the invention and equally apply here. It is of note that in accordance with this invention, also fragments of the nucleic acid molecules as defined herein above and as, in particular, depicted in SEQ ID NOs: 3 to 4 may be employed in gene therapy approaches. Said fragments comprise the nucleotide at position -13910 as defined in (c) herein above (and also shown in SEQ ID NO: 3) or position -22018 as defined in (d) herein above (and as shown in SEQ ID NO: 4). Preferably, said fragments comprise at least 200, at least 250, at least 300, at least 400 and most preferably at least 500 nucleotides.
In a preferred embodiment of the use of the invention said gene therapy treats or prevents adult-type hypolactasia.
5 The figures show:
Fig. 1 : The Finnish adult-type hypolactasia families studied. Blackened symbols indicate hypolactasic individuals, asterisk (*) indicate that no sample was available, question mark (?) indicates unknown affection status. | indicates 0 the individuals used for sequencing for SNP identification (Table 2).
Fig 2: Physical map of adult-type hypolactasia locus. BAC clones are shown above the horizontal line. The three genes LPH, MCM6 and DARS are shown by thick black arrows with the tip pointed toward the 3 "end of the gene above 5 the black boxes. The position of ten polymorphic microsatellite markers used for fine mapping of the locus are shown. The backslash in the horizontal line denotes a gap in the sequence of the contig sequence. The position of marker D2S2169 was confirmed by bridging the gap with PAC 106020 isolated from the PAC library as described before40. The organisation of the
!0 MCM6 gene is shown including the position of the lactase persistent phenotype-associated variants in introns 9 and 13 located 13.9 kb and 22 kb 5' of the first ATG of LPH.
Fig. 3: Extended haplotype analysis of the persistent chromosomes derived from 5 Finnish adult-type hypolactasia families using seven closely liked microsatellite markers.The haplotypes representing the ancestral founder persistent chromosome are shaded. Only the haplotypes of non-persistent chromosomes that were also present in the persistent chromosomes are shown. On the basis of ancestral recombinations, the adult-type hypolactasia D locus could be restricted to 47 kb interval between markers LPH1 and AC3.
Fig. 4: The sequence comprised in the sequence of intron 13 of the MCM6 gene (3220bp) comprising the SNP at position -13910 in which the T, which is
specific for the lactase persistence, is substituted by a C. Said position is indicated by the use of a small letter. This sequence refers to SEQ ID NO:1.
Fig. 5: The sequence comprised in the sequence of intron 9 of the MCM6 gene(1295bp) comprising the SNP at position -22018 in which the A, which is specific for the lactase persisting-type sequence is substituted by a G. Said position is indicated by the use of a small letter. This sequence refers to SEQ
ID NO:2.
Fig. 6: The sequence of the lactase persisting-type intron 13 of the MCM6 gene (3220bp) comprising at position -13910 a T. Said position is indicated by the use of a small letter. This sequence refers to SEQ ID NO:3.
Fig. 7: The sequence of the lactase persisting-type intron 9 of the MCM6 gene(1295bp) comprising at position -22018 an A. Said position is indicated by the use of a small letter. This sequence refers to SEQ ID NO:4.
Fig. 8: The sequence of intron 13 of the MCM6 gene (3220bp) comprising the SNP at position -13910 in which the T, which is specific for the lactase persisting- type sequence is substituted by a C. Said position is indicated by the use of a small letter. This sequence refers to SEQ ID NO:5.
Fig. 9: The sequence of intron 9 of the MCM6 gene(1295bp) comprising the SNP at position -22018 in which the A, which is specific for the lactase persisting- type sequence is substituted by a G. Said position is indicated by the use of a small letter. This sequence refers to SEQ ID NO:6.
The examples illustrate the invention.
Example 1: Linkage and linkage disequilibrium analysis
Seven polymorphic microsatellite markers between D2S114 and D2S2385 flanking the LPH gene on 2q21 were analyzed in nine extended Finnish hypolactasia families (Fig. 1). Significant evidence for linkage was found with markers D2S314, D2S442, D2S2196 and D2S1334, with a maximum lod score of 7.67 at θ =0 obtained with marker D2S2196 (Table 1). Obligatory recombination events were detected with marker D2S114 (family B, IV3), which defines the centromeric boundary for the lactase persistence/non-persistence locus, and with marker D2S2385 (family B, IV17) (Fig. 1 , Table 1), which defines the telomeric boundary of the locus. To fine map the critical region, nine additional polymorphic markers were analyzed (Table 1). Linkage disequilibrium (LD) over the region was monitored conditional on the detected linkage treating the allele frequencies and the recombination fraction as nuisance parameters16" 17. Six out of nine markers (LPH13, LPH2, LPH1 , AC3, AC4, and AC10), spanning over ~200kb interval showed highly significant evidence of LD (p < 10"4) whereas markers 3" from the LPH gene showed no evidence of LD (Table 1). Two markers, LPH2 and AC3, displayed the most significant linkage disequilibrium in the lactase persistence alleles (p<10"7).
The family material consisted of nine extended Finnish pedigrees originally studied by Sahi5. All family material was tested for adult-type hypolactasia in the 1970s. The family material for this study was enlarged by collecting the DNA of the family members in the younger generations. The family material in this study consisted of 194 individuals in total (Fig. 1). The phenotypic status of all family members was confirmed by lactose tolerance tests with ethanol (LTTE)4"5 in all but 49 individuals. Gluten enteropathy has been excluded in all affected patients by measurement of the serum IgA anti-tissue transglutaminase45. DNA was extracted from blood samples taken from all participating family members in accordance with standard protocols46, after obtaining informed consent. As a case-control study 196 random DNA samples isolated from jejunal biopsy specimens from which disaccharidase activities had been measured47 at the Helsinki University Hospital were sequenced. DNA was isolated
from intestinal biopsies according to the standard protocol46. These series comprised 137 lactase persistent and 59 non-persistent samples. In addition DNA from nine Italian, kindly provided by M. Rossi, University of Naples, nine German DNA samples, kindly provided by M. Lentze, University of Bonn and twenty two South Korean, kindly provided by J.K. Seo, Seoul National University, intestinal biopsy sample specimens were analyzed (In the table: 23 Korean, 9 Italian and 7 Germans (One of the cases from Germany originated from South Korea). The diagnosis was based on the measurement of disaccharidase activities. Finally, to determine the frequency of the
variant in the Finnish population, the DNA of 938 anonymous Finnish blood donors from small parishes from Eastern and Western Finland and the DNA of 109 parents belonging to the CEPH families19 were analyzed. In addition, genomic DNA from a baboon (Papio hemedryas ussinus) isolated from liver biopsy using standard protocols48 was analyzed. The study was approved by the Ethical Committees of the Helsinki University Hospital and the Finnish Red Cross Blood Transfusion Service.
Example 2: Extended haplotype analysis
In the first stage ten highly polymorphic microsatellite markers flanking the LPH gene on 2q21 were analyzed as described elsewhere40,55. Briefly, the ten highly polymorphic microsatellite markers on 2q in the vicinity of the lactase gene from The Genethon Resource Center55 were analyzed with genetic distances as follows: cen - D2S114 - 1cM - D2S1334 - OcM - D2S2196 - OcM - D2S442 - 2cM - D2S314 - 2cM - D2S2385 - 1cM - D2S2288 - 1cM - D2S397 - 1cM - D2S150- 1cM - D2S132. The order of the markers has been mostly obtained from the physical YAC contig map of chromosome 2 (Chumakov et al. 199556) supplemented with the Genethon map. PCR was performed in a total volume of 15 ul containing 12ng of template DNA, 5pmol of primers, 0.2mM of each nucleotide, 20mMTrisHCI (pH 8.8), 15 mM (NH ) S04, 1.5 mM MgCI2l 0.1% Tween 20, 0.01% gelatin and 0.25U Taq polymerase (Dynazyme, Finnzymes). One of the primers was radiolabeled at the 5' end with 3 P-γATP. The reactions were performed in a multiwell microtitre plate for 35 cycles with denaturation at 94 °C for 30s, annealing at various temperatures
depending on the primers for 30s and extension at 72 °C for 30s; denaturation was set at 3min and final extension at 5min. The amplified fragments were separated on 6% polyacrylamide gei, and autoradiography was performed. In the second stage, nine additional microsatellite markers within the contig constructed over the LPH gene were identified from the published genomic sequence of the BACs (NH034L23, NH0318L13, NH0218L22, and RP11-32911) using the Repeat Masker program (http://ftp.genome.washington.edu/cgi-bin/RepeatMasker). Primers flanking the repeats were synthesized. PCR conditions were as described elsewhere40. The amplified fragments were separated on 6% polyacrylamide gel, and autoradiography was performed.
Pairwise lod scores were calculated by use of the MLINK option of the LINKAGE program package49. Autosomal recessive inheritance for adult-type hypolactasia with complete penetrance, no sex difference in recombination fractions, and a disease allele frequency of 0.4 was assumed. Only individuals above 20 years of age were included in the study as the condition is manifested by that age in the Finnish population5"6. The affection status for individuals not confirmed by LTTE was regarded as unknown. Allele frequencies and heterozygosities for the markers were estimated from family material using the Downfreq program for purposes of the parametric linkage analysis49. Additionally, pseudomarker linkage and linkage disequilibrium analyses were performed, assuming autosomal recessive mode of inheritance16. A test of LD was performed conditional on the detected linkage treating the allele frequencies and the recombination fraction as nuisance parameters16,49. P- values from these analyses are shown in Table 1. Haplotypes were constructed manually for the microsatellite markers in this order: LPH1-LPH2-LPH13-AC7-AC3- AC4-AC5 (Fig. 3). A total of 54 non-persistent chromosomes and 33 persistent chromosomes in our family material were available for haplotype analysis.
The order of the closely linked markers was confirmed by assembling four BAC- clones NH0034L23, NH0218L22, NH0318L13 and 329110 in the critical region into one uninterrupted sequence segment. This contig extended from marker AC8 to the exon 10 of the aspartyl-tRNA synthetase (DARS) gene and covered a total of 222,5 kb (Fig. 2). Based on this physical map of the linked region, extended haplotypes
with seven markers covering a 150 kb interval (cen-LPH13-LPH2-LPH1-AC7-AC3- AC4-AC5-tel) (Fig. 3) were constructed. One major haplotype was present in 20 persistence alleles (60%) versus 3 of the non-persistence alleles (5%), whereas a wide diversity of haplotypes was observed in non-persistence alleles. The remaining 40 % of the haplotypes in the persistence alleles differed from the ancestral haplotype in a manner consistent with a breakdown of the haplotype by historical recombination events. Based on the conserved haplotype analysis, the locus for lactase persistence could be restricted to a 47 kb interval between markers LPH1 and AC3 (Fig.3)
Example 3: Sequence analysis of the adult-type hypolactasia locus
The 47 kb region between the markers LPH1 and AC3 was amplified in overlapping PCR fragments from genomic DNA of several members of the nine hypolactase families and sequenced. The region contains the minichromosome maintenance (MCM6) gene18, which covers 36 kb of the critical 47 kb region (Fig. 2). No variations were detected in the coding region of the MCM6 gene but total of 52 variants; 43 SNPs and 9 deletion/ insertion polymorphisms, were identified in the critical 47 kb region (Table 2). Only two of the variants (C/T.139io,
were associated with the lactase persistence/ non-persistence trait in the Finnish families (Tables 2 and 3). The first associated variant, C/T -13910, resides in intron 13 of the MCM6 gene at position -13910 bp from the first ATG-codon of the LPH gene. The second associated variant, G/A 22oιβ.is located in intron 9 of the MCM6 gene at position - 22018 from the first ATG-codon of the LPH gene (Fig.2). These two variants, 8 kb apart from each other, completely cosegregated with adult-type hypolactasia in nine extended Finnish families. All hypolactasic (non-persistent) family members were homozygous for both C13910 and G.22018 (Table 3). Interestingly, both these variants reside in repeat elements, C/T-139ιo in an L2-derived element and G/A.22018 in an Alu element.
Experimentally, three non-persistence, 2 homozygous persistence and 2 heterozygous persistence individuals sharing a similar haplotype across the critical
region from our family material were used for sequencing in the first stage (Fig. 1). Using the published draft genomic sequence of the BACs: NH0034L23, NH0218L22 NH0318L23, and RP-329110 that covered the critical region of adult-type hypolactasia were assembled to one contig using Sequencher 4 software (Gene Codes Corporation). Oligonucleotide primers spanning the critical region between markers LPH1 and AC3 were designed (a list of oligonucleotide primers described herein below). PCR amplifications were carried out in a 50 μl volume with genomic DNA (100 ng), primers (20 ng each), dNTPs (200 μM), 0.5 U of Taq polymerase (Dynazyme, Finnzymes) in a standard buffer. Most PCR were amplified using the following PCR cycle conditions: an initial round of denaturation at 94 °C for 3 min, then 35 cycle at 94°C at 30 s, 55 °C for 30 s, and 72 °C for 1.25 min and a final extension of 72 °C for 10 min, except that in cases where the size of the PCR products were more than 1kb we used the Dynazyme extend kit (conditions are described herein below). Purified PCR products (15-40 ng) were cycle sequenced using BigDye terminator chemistry (PE Biosystems). Data were analyzed using ABI Sequencing Analysis 3.3 (PE Biosystems) and Sequencher 4.1 (Gene Codes). Detection of the Lactase variants by Sequencing:
PCR amplifications were carried out in a 50 μ\ volume with genomic DNA (100 ng), primers (20 ng each), dNTPs (200 μ ), 0.5 U of Taq polymerase (Dynazyme, Finnzymes) in a standard buffer. Both PCRs were amplified using the following PCR cycle conditions: an initial round of denaturation at 94°C for 3 min, then 35 cycles at 94°C at 30 s, 55°C for 30 s, and 72°C for 1.25 min and a final extension of 72°C for 10 min. PCR were purified by enzymatic reaction. Purified PCR products (15-40 ng) were cycle sequenced using BigDye terminator chemistry (PE Biosystems). Data were analyzed using ABI Sequencing Analysis 3.3 (PE Biosystems) and Sequencher 4.1 (Gene Codes).
Screening of the lactase variants by solid-phase minisequencing: The DNA fragment spanning the C T.13910 variant was amplified using one biotinylated (5'-Bio-ccτcGTTAATACCCACTGACCTA-3') primer and unbiotinylated (5'- GTCACTTTGATATGATGAGAGCA-3') primer. For G/A.22018 biotinylated (5'-Bio- TGCTCAGGACATGCTGATCAA-3') and one unbiotinylated (5'-
CTACCCTATCAGTAAAGGCCTA-3') primer were used under conditions described
above. 10 μl of the PCR product was captured in a streptavidin coated microtiter well (Lab systems, Finland). The wells were washed, and bound DNA was denaturated as described by Syvanen et al. (Am J Hum Genet. (1993), 52, 46-59) and Syvanen and Landegren (Hum Mutat. (1994), 3, 172-9). 50 μ\ of the minisequencing reaction mixture contained 10 pmoles of the minisequencing primers for C/T.13915 (5'-
GGCAATACAGATAAGATAATGTAG-3') , G/A-22018 (5'-AAAAACAGCATTCTCAGCTGGGC-3') , and 0.1 μl of either H-dCTP, H-dGTP corresponding to the lactase non-persistence allele (115 Ci/mmol; Ammersham, UK) or H-dTTP, H-sATP corresponding to the lactase persistence allele and 0.05 units of DNA polymerase (Dynazyme II, Finnzymes) in its buffer was added to each well. The microtiter plates were incubated for 20 min at 50°C, and the wells ere washed. The detection was eluted, and the eluted radioactivity was measured in a liquid scintillation counter (Rackbeta 1209, Wallac, Finland). Two parallel minisequencing reactions were carried out for each PCR product. PCR primers and detection primer for the C/T.13910 variant: Forward PCR primer: GTCACTTTGATATGATGAGAGCA Tm 58 SEQ ID NO: 8 Detection primer: GGCAATACAGATAAGATAATGTAG Tm 58 SEQ ID NO: 10
Bio-Reverse primer: B:LO-CCTCGTTAATACCCACTGACCTA Tm 62 SEQ ID NO: 9 or Bio-TAGGTCAGTGGGTATTAACGAGGT SEQ ID NO: 7 PCR primers and detection primer for the G/A.22018 variant: Forward PCR primer: CTACCCTATCAGTAAAGGCCTA Tm 58 SEQ ID NO: 12 Detection primer: AAAAACAGCATTCTCAGCTGGGC Tm 62 SEQ ID NO: 14
Bio-Reverse primer: BIO-TGCTCAGGACATGCTGATCAA Tm 62 SEQ ID NO: 13 or Bio-TTGATCAGCATGTCCTGAGCA SEQ ID NO: 11
Example 4: Monitoring the DNA-variants in a case/ control study sample
The frequency of the C/T.139io and G/A -22018 variants was analyzed in DNA samples isolated from a total of 196 intestinal biopsy samples specimens which had been analyzed for disaccharidase activity as a diagnostic test for hypolactasia. A total of 59 samples showed primary lactase deficiency. Six out of 59 cases (Table 3) were heterozygous GA for the G/A .22018 variant, the remaining 53 being homozygous for the G allele. All 59 samples were homozygous for the C allele of the variant C/T.13910.
Among the 137 cases showing lactase persistence, 74 were found to be homozygous for alleles T and A, 63 being heterozygous CT and GA and none being homozygous for alleles C and G at C/T.13910 and G/A -22018 , respectively (Table 3).
To analyze these variants in other populations, DNA samples isolated from intestinal biopsy specimens from 40 non-Finnish cases with established disaccharidase deficiency were sequenced: 23 cases originated from South Korea, 9 from Italy and 8 from Germany. One Italian case was heterozygous GA for G/A -22018 whereas all remaining 39 cases were homozygous CC and GG for C/T -13910 and G/A -22018 respectively (Table 3). An extended study gave rise to the data provided in Table 7 representing data of the complete association of C/T.13910 variant with the biochimcally verified hypolactasia (lactase non-persistence) in 400 individuals for 6 different populations. The G/A.22018 variant was associated with the lactase non- persistence in 400 out of 401 cases.
Example 5: Molecular epidemiology of the lactase persistence variant C T.13910
To monitor for the prevalence of the hypolactasia-associated variant in the Finnish population a solid-phase minisequencing method19,20 was used to screen DNA samples of 938 anonymous Finnish blood donors originating either from the Western early settlement region or the Eastern late settlement region of Finland (Table 4). Experimentally, the DNA fragment spanning the C/T.13910 variant was amplified using one biotinylated (5X-CCTCGTTAATACCCCTGACCTA-3 ) primer and unbiotinylated (5N- GTCACTTTGATATGATGAGAGCA-3^) primer. For G/A.22018 we used one biotinylated (5N-AGTCTGTGGCATGTGTCTTCATG-3^) and one unbiotinylated f 5- TGCTCAGGACATGCTGATCAACT-3^) primer under conditions described above. 10 μl of the PCR product was captured in a streptavidin coated microtitre well (Lab system, Finland). The wells were washed, and the bound DNA was denatured as described previously19,20, 50 μl of the minisequencing reaction mixture contain 10 pmoles of the minisequencing primers for G/A.22005 (5'- GACAAAGGTGTGAGCCACCG-3 ), G/A.13915 (5*-
GGCAATACAGATAAGATAATGTAG-3 ) and 0,1 μl of either H-dCTP corresponding
to the lactase non-persistence allele (115 Ci/mmol; Amersham, UK) or H-dTTP corresponding to the lactase persistence allele and 0.05 units of DNA polymerase (Dynazyme II, Finnzymes) in its buffer was added to each well. The microtiter plates were incubated for 20 min at 50 °C, and the wells were washed. The detection primer was eluted, and the eluted radioactivity was measured in a liquid scintillation counter (Rackbeta 1209, Wallac, Finland). Two parallel minisequencing reactions were carried out for each PCR product. The overall prevalence of the putative hypolactasia genotype CC-13910 (170 cases) was 18.1%, with higher prevalence (16.8% versus 18.9%) in the western than in the eastern sample (Table 4). These values are in good agreement with the epidemiological study reporting the prevalence of 17% among Finnish speaking Finns with an increasing gradient from West to East2. The same set of samples for the G/A.22018 polymorphism was also genotyped, and the LD between these two SNPs monitored using the Dx statistic21. They were found to be in almost complete LD (D' = 0.98, p = 7.62 x 10"11, Table 5).
The prevalence of hypolactasia in different populations is known to vary greatly from less than 5% to almost 100%3,6. To determine whether these changes in hypolactasia prevalence would correlate with the distribution of the genotype CC13910, the DNA of the parents of CEPH families22 was analyzed. CEPH families have been mainly collected from France, with reported prevalence of hypolactasia around 37% 23 and Utah, the Utah populations originating from Northern Europe with prevalence of hypolactasia less than 5%24. Genotyping of the parents in CEPH families revealed that 41 ,2% (7 out of 17 samples) of French families have the genotype CC whereas only 7,6% (7 out of 92 samples) of Utah families have the genotype CC (Table 4). Again, despite the small number of analyzed samples these figures agree with the values obtained in the epidemiological studies of hypolactasia in these populations 23,24.
Table 8 demonstrates that the observed prevalence of the variants well agrees with the described population frequencies of the lactose intolerance.
Example 6: The genealogy of the lactase persistence variant C T.139io
Haplotype analysis in the Finnish families suggested that most if not all, lactase persistence alleles in Finland have descended from one common ancestor. Linkage disequilibrium was used to estimate the time of the introduction of the persistence allele into the Finnish population25. Assuming 20 years generation time, this estimate would indicate that the founder mutation was introduced into the Finnish population some 9000-11400 years ago (Table 6). This is in good agreement with earliest signs of settlement in the Finnish mainland some 8000-9000 years ago26 and would reasonably well coincide with the beginning of the dairy farming in 8000-10.000 BC27. More importantly, the presence of the same DNA-variant in persistence alleles in different populations would suggest that this variant is even more ancient and the mutation has occurred before differentiation of the analyzed populations.
To get some insight into the phylogenetic origin of the lactase allele, intron 9 and part of intron 13 of the MCMδ gene of a Baboon (Papio Hamadryas) were sequenced. Genotype GG and CC was present in Baboons DNA at both G/A.22018 and C/T_ι39io- This could suggest that alleles G and C, respectively reflect the appearance of the ancestral allele, presenting the non-persistence type and a mutation has transformed this allele to create the persistence allele. This assumption is supported by the identification of the LD and shared haplotype in the persistence alleles versus a high diversity of alleles found in non-persistence alleles.
Example 7: Pairwise LD of C/T and G/A variants.
Pairwise LD between C/T.13910 and G/A.22018 was estimated using the D' statistic21. Haplotype frequencies were estimated by maximum likelihood using the EH program50. D is calculated as max(D/ Dmaχ, D/Dmin) : where disequilibrium measure D = hpcr— p q, where hpq is the frequency of the haplotype with rare allele at each locus, p and q are frequency of the rare alleles at loci 1 and 2 , and Dmax = min p(1-p),q(1-q) if D>0, and Dmiπ = -min pq, (1-p)(1-q) if D<0. The significance of devitationf of D' from 0 was
determined using the statistic D2 which is distributed as χ2 with 1 df 21
Gene accessions numbers. For BACs NH0218L22, N0034L34, NH0318L13, and RP11-329110 are AC012551 , AC011893, AC011999 and AC016516 respectively. The accession numbers for human polymorphisms are GenBank AF395607- AF395615.
References
1. Flatz, G. & Rotthauwe, H. The human lactase polymorphism: physiology and genetics of lactose absorption and malabsorption. Prog. Med. Genet 2, 205- 249 (1977). 2. Sahi, T.,. Isokoski, M., Jussila, J. & Launiala, K. Lactose malabsorption in Finnish children of school age. Acta Paediatr Scand.61ι, 11-16 (1972).
3. Wang, Y. et al. The genetically programmed down-regulation of lactase in children. Gastroenterology. 114:1230-1236 (1998).
4. Sahi, T., Isokoski, M., Jussila, J., Launiala, K. & Pyόrala, K. Recessive inheritance of adult-type lactose malabsorption. Lancet.823-826 (1973).
5. Sahi, T. The inheritance of selective adult-type lactose malabsorption. Scand. J. Gastroenterol. suppl. 30, 1-73(1974).
6. Sahi, T. Genetics and epidemiology of adult-type hypolactasia. Scand. J. Gastroenterol. Suppl.202, 7-20 (1994). 7. Boll, W., Wagner, P. & Mantei, N. Structure of the chromosomal gene and cDNAs coding for lactase-phlorizin hydrolase in human with adult-type hypolactasia or persistence of lactase. Am . Hum. Genet. 48; 889-902 (1991)."
8. Mantei, N. et al. Complete primary structure of human and rabbit lactase- phlorizin hydrolase: implications for biosynthesis, membrane anchoring and evolution of the enzyme. EMBO J. 7, 2705-2713 (1988).
9. Wang, Y. et a/.The lactase persistence/non-persistence polymorphism is controlled by a cis-acting element. Hum. Mol. Genet A, 657-662 (1995).
10. Harvey, C.B., Pratt, W.S., Islam, I., Whitehouse, D.B. & Swallow, D.M. DNA polymorphisms in the lactase gene: linkage disequilibrium across the 70 kb region. EurJ. Hum. Genet. 3, 27-41 (1995). 11. Escher, J.C et al . Molecular basis of lactase levels in adult humans. J. Clin. Invest. 89, 480-483 (1992).
12. Lloyd, M et al. Regulation of intestinal lactase in adult hypolactasia. J. Clin. Invest. 89, 524-529 (1992).
13. Fajardo, O., Naim, H.Y. & Lacey, S.W. The polymorphic expression of lactase in adults is regulated at the messenger RNA level. Gastroenterology 106, 1233-
14. Luigi, M. et al. Mosaic regulation of lactase in human adult-type Gastroenterology 112, 1506-1514 (1997).
15. Rossi, M. et al. Lactase persistence versus decline in human adults:Multifactorial events are involved in down-regulation after weaning. Gastroenterology 112, 1506-1514 (1997).
16. Goring, H.H.H. & Terwilliger, J.D. Linkage analysis in the presence of errors IV: Joint pseudomarker analysis of linkage and / or linkage disequilibrium on a mixture of pedigrees and singletons when mode of inheritance cannot be accurately specified. Am. J. Hum. Genet. 66, 1310-1327 (2000). 17. Terwilliger, J.D. & Goring, H.H.H. Gene mapping in the 20th and 21st centuries: Statistical methods, data analysis, and experimental design. Hum. Biol. 72, 63- 132 (2000).
18. Harvey, C.B. et al. Regional localization of the lactase-phlorizin hydrolase, LCT, to chromosome 2q21. Ann. Hum. Genet. 57, 179-185 (1993).
19. Syvanen,A-C, Sajantila, A., Lukka, M. Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am. J. Hum. Genet 52, 46-59 (1993).
20. Syvanen,A-C. & Landegren, U. Detection of point mutations by solid-phase methods. Hum. Mutat. 3, 172-179 (1994)
21. Thompson, E. A., Deeb, S., Walker, D. & Motulsky, A. G. The detection of Linkage disequilibrium between closely linked markers:RFLPs at the AI-CIII
Apolipoprotein genes. Am. J. Hum. Genet. 42, 113-124 (1998).
22. Dausset, J. et al. Centre d 'etude du polymorphisme humain (CEPH): Collaborative genetic mapping of human genome. Genomics 6, 575-577 (1990).'
23. Cuddenec, Y., Delbrϋck, H. & Flatz, G. Distribution of the adult lactase phenotypes- lactose absorber and maiabsorber-in a group of 131 army recruit Gastroenterol.Clin. Biol. 6, 776-779 (1982).
24. McLellan, T., Jorde, L.B. & Skolnick, M.H. Genetic distance between the Utah Mormons and related populations. Am. J. Hum.Genet. 36, 836-857 (1984).
25. Terwilliger, J.D. A powerful likelihood method for the analysis of linkage
disequilibrium between trait loci and one or more polymorphic marker loci. Am. J. Hum. Genet. 56, 777-787 (1995).
26. Nunez, M.G. A model of the early settlement of Finland. Fennosscandia archaelogica IV, 3-18 (1997).
27. Simoons, F.J. Primary adult lactose intolerance and the milking habit: a problem in biological and cultural interrelations.il. A cultural historical hypolthesis. Am. J. Dig. Dis.16, 695-710 (1970).
28. Varilo, T. et al The age of human mutatio genealogical and linkage disequilibrium analysis of the CLN5 mutation in the Finnish population. Am. J. Hum. Genet. 58, 506-512 (1996).
29. Hastbacka, J. et al. Linkage disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland. Nature Genet. 2: 204-211 (1992).
30. Harvey C.B. et al. Lactase haplotype frequencies in Caucasians: association with the lactase persistence/non persistence polymorphism. Ann Hum Genet 62, 215-223 (1998).
31. Ohtani, K. et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 18, 2299- 2309 (1999).
32. Smith, A.F.A. The origin of interspersed repeats in the human genome. Curr. Opin. Genet. Dev. 6, 743-748 (1996).
33. Kazazian, H.H. & Moran, J.V. The impact of L1 retrotransposons on the human genome. Nature Genet. 19, 19-24 (1998).
34. Moran, J.V., DeBerardinis, R.J. & Kazazian, H.H. Exon shuffling by L1 retrotransposition. Science 283, 1530-1534 (1999). 35. Wei, W. et al. Human L1 retrotransposition: cis preference versus trans complementation. Mol. Cell. Biol. 21 , 1429-1439 (2001).
36. Donnelly, S.R., Hawkins. T.E. & Moss, S.E. A conserved nuclear element with a role in mammalian gene regulation. Hum. Mol. Genet, vol.8, 9,1723-1728 (1999).
37. Boeke, J.D. LINEs and Alus - the polyA connection. Nature Genet. 16, 6-7 (1997). 38. Jurka, J. Sequence patterns indicate an enzymatic involvement in integration of mammalians retroposons. Proc. Natl. Acad. Sci. U.S.A. 94, 1872-1877 (1997).
39. Savilahti E, Launiala K, Kuitunen P. Congenital lactase deficiency. Arch. Dis. Child. 58, 246-252 (1983).
40. Jarvela, I. et al. Assignment of the locus for congenital lactase deficiency to 2q21 , in the vicinity of but separate from the lactase-phlorizin hydrolase gene. Am. J. Hum. Genet. 63, 1078-1085 (1998).
5
41. Simoons, F. J. The geographic hypothesis and lactose malabsorption. A weighing of the evidence. Am. J. Dig. Dis. 23, 963-980 (1978).
42. Flatz, G. & Rotthauwe, H, W. The human lactase polymorphism: physiology and 0 genetics of lactose absorption and malabsorption. Prog. Med. Genet. 2, 205-
249 (1977).
43. McCracken, R.D. Lactase deficiency: an example of dietary evolution. Curr. Anthropol. 12, 479-517 (1971).
44. Aroia, H. et al. Diagnosis of hypolactasia and lactose malabsorption. Scand. J. Gastroenterol. Suppl. 202, 26-35 (1994).
45. Sulkaneπ, S. et al. Tissue transglutaminase autoantibody enzyme-linked 0 immunosorbent assay in detecting celiac disease. Gastroenterology 115 (6),
1322-1328 (1998).
46. Sambrook, J., Fritsch, E.F. & Maniatis, T. Molecular cloning: a laboratory manual, (2nd ed). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 5 N.Y. (1989).
47. Messer, M. & Dahlqvist. A. A one - step ultramicro method for the assay of intestinal disaccharidases. Anal. Biochem. 14 (3), 376-92 (1966). 0 48. Cottingham, Jr. R.W., Idury, R.M. & Schaffer, A.A. Faster sequential genetic linkage computations. Am. J. Hum.. Genet. 53, 252-263 (1993).
49. Goring, H.H.H. & Terwilliger, J.D. Linkage analysis in the presence of errors III: Marker loci and their map as nuisance parameters. Am. J. Hum. Genet. 5 66,1298-1309 (2000).
50. Terwilliger, J.D. & Ott, J. Hand book of human genetic analysis. Johns Hopkins University Press, Baltimore (1994).
10 51. Osborne et al., Curr. Opin. Chem. Biol. I (1997), 5-9
52. Stall and Szoka, Pharm. Res. 12 (1995), 465-483
53. Harlow and Lane „Antibodies, A Laboratory Manual", CSH Press, Cold Spring tδ Harbor, USA, 1988
54. Higgins and Hames (eds.), "Nucleic acid hybridization, a practical approach", IRL Press, Oxford 1985
55. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996 Mar 14;380(6570): 152-4.
56. Chumakov IM, Rigault P, Le Gall I, Bellanne-Chantelot C, Billault A, Guillou S, Soularue P, Guasconi G, Poullier E, Gros I, et al. A YAC contig map of the human genome. Nature. 1995 Sep 28;377(6547 Suppl): 175-297
Table 1. Linkage and Linkage Disequilibrium Analyses in aduit-type hypolactasia families (fine mapping markers shown in bold)
Marker Lod score(Z) at Θ - valuea
0.0 0.1 0.2 0.3 0.4
D2S114 -oo 2.44 1.92 1.13 . 0.41 0.87195
P6112 2.76 2.20 1.45 0.75 0.22 0.66207
D2S1334 3.15 2.45 1.61 0.84 0.25 0.91039
AC8 2.26 1.99 1.36 0.71 0.21 0.53670
LPH13 3.67 2.94 1.96 1.03 0.31 4x10'°
LPH2 4.09 3.07 2.00 1.00 0.26 5.7xl0"7
LPH1 5.91 4.52 2.96 1.53 0.46 5xl0"6
AC7 3.63 2.60 1.66 0.83 0.23 0.03471
AC3 6.63 4.88 3.16 1.61 0.44 3.2xl0"8
AC4 3.07 2.22 1.42 0.71 0.19 4x10-5
AC5 5.33 4.10 2.72 1.39 0.39 0.02166
AC10 6.60 4.99 3.25 1.65 0.46 lxlO"5
D2S2196 7.67 • 5.62 3.62 1.85 0.54 0.00010
D2S442 3.81 3.08 2.08 1.03 0.27 0.22805
D2S314 4.22 3.61 2.50 1.37 0.45 0.27535
D2S2385 -oo 2.79 1.92 1.01 0.28 0.46457 a: ^-values produced using linkage disequilibrium test given linkage T W
Table 2. The variations identified within adult-type hypolactasia locus in the Finnish Families
Positiona Variant Lactase Lactase Lactase persistence persistence non-persistence (Homozygous ) (Heterozygous) BIV4 AIN3 BIN8 Cr 3 BIN9 DIN4 EIII2b
-694 A→G AA AA AG AA GG Ν° AA
-1640/50 T →TI2 TB B TΏ/B TD/B T1313 TΏ/Ώ T^ΌIΏ. ^ i
-2131 C→T CC CC CT CC TT CT* TT
-3058/72 Ti5→T16 Toiα Tms Tm5 T15/15 T1515 Tmβ 6
-3075 G→T GG GG GG GG GG GG TT
-4480 T→A TT TT TA TΓ AA TT TT
-5440 C→T CC CC CT CC TT CC CC
-5926 A→T AA AA AA AA AA TA TT
-8540 G→A GG GG GA GA AA AG AA
-8630 C→G CC CC CG CG GG GC GG
■13495 T→C TT TT TC TT CC CT CC
-13910 T→C TT TT TC TC CC CC CC
-15239 G→A GG GG GA GG AA AG AA
-15862 T→C CC CC CT CC TT TC TT
-16568/79 Tπ→Tπ Tπ/n Tπ/11 π i2 Tiiin T12/12 Tnni Tn/u
-16888 A→G AA AA GA AA GG GA GG
-17300 C→T CC CC CC CC CC CT TT
-19044 T→C TT TT TC TT CC CT CC
-19519 T→C TT TT TC TT CC TT TT
-20077 C→G CC CC CG CC GG GC GG
-20486 G→A GG GG GA GG AA GG GG
-21721/28 A7→A6 A7/7 A7 7 A7/7 A7/7 A7/7 A7/A6 A7/7
-21731 A→C AA AA AA AA AA CC AA
-21736/43 A9→A8 A9 9 A9/9 A9/A8 A9/9 Ag/8 A8/8 A8/8
-22018 G→A AA AA AG AG GG GG GG
-22741 C→T CC CC CC CC CC N TT
-22788 A→G AA AA AG AA GG N GG
-23069 A→G AA AA AG AA GG N GG
-23442 A→G AA AA AA AA AA N GG
-23771 T→C TT TT TT TT TT N CC
-25093/23 Δ30 bp Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ N II
-27310 A→/G AA AA AG AA GG GA GG
-27480 G→A GG GG GA GG AA AG AA
-27807 A→C AA AA AA AA AA AC CC
-30183 A→G AA AA AG AA GG AA AA
-31268 A→G AA AA AG AA GG AA AA
-31342 T→C TT TT TT TT TT CT CC
-33645 C→T CC CC CT CC TT CC CC
-35176 T→C TT TT TC TT CC CT CC
-36254 C→T CC CC CT CC TT TC TT
-36296 G→T TT TT TG TT GG TG N
-36501 A→T AA AA AT AA TT AT N
-36506/14 Δ 9 bρ ΔΔ ΔΔ Δ I ΔΔ II Al N
-36671/77 T7→T6 T7/7 T /7 T7/6 T /7 T6/6 T7/7 T7/7
-37565 T→G TT TT TG TT GG GG TG"
-38276 G→C GG GG GC GG CC GG GG
-39036 G→C GG N GC N CC N N
-40608 G →C GG GG GG GG GG GC CC
-41590 T→C TT TT TC TT CC CT CC
-42081/82 ΔAG AG AG AG/Δ AG ΔΔ AG AG
-42618 T→C TT TT TC TT CC TT TT
-42893 G→A GG GG GA GG AA GG GG
a: The Number is from initiation translation codon (ATG) of the LPH gene using the compiled genomic sequence of the BACs NH034L23, NH0218L22, NH0318L13 and RP11-329110 , b: the individuals sequenced from the Finnish families studied and showed by arrow in fig.1. c: not determined
Table 3. Distribution of C/T.ι3910 & G/A _220ι8 genotypes in lactase persistent/non-persistent alleles
C/T-U9U) G/A -22018 Total
Genotype CC CT TT GG GA AA
Family members Lactase non-persistence 45 0 0 45 0 0 45
Lactase persistence 0 32 13 0 32 13 45
Case-control samples
Finnish Lactase non-persistence 59 0 0 53 6 0 59
Lactase persistence 0 63 74 0 63 74 137
Non-Finnish a Lactase non-persistence 40 0 0 39 1 0 40
Lactase persistence 0 5 0 0 5 0 5
Total Lactase non-persistence 0 144 Lactase persistence 187 a: non-Finnish samples consist of 23 South Korean, 9 Italian and 7 German individuals
Table 4. Prevalence of the C/T-13910 variant in population samples
DNA samples % (CC) analysed ) genotype
I. Finnish population:
1. Eastern regions 0 18.9%
2. Western regions 15 16.8%
Total 2 18.1%
II. CEPH parents:
1. Utah families 5 7.6%
2. French families 4 41.2%
A total of 938 DNA sample small parishes
from Eastern and Western from CEPH
parents. The prevalence of y the genotype frequencies of CC alleles.
Table 5. LD between C/T-13910 and G/A-220018 variants in random Finnish samples
Genotype at C/T.13910 Total Ev χ2(l df) P-value
_ __ __.
Genotype at G/A22ooιs GG 162 165
GA 440 449
AA 318 324
Total 170 446 322 938 0.984 42.41 7.62x10 -11
LD was calculated using D statistic τι , p value is tlie significance of D' from 0 as described in methods πr .
Table 6. Estimation of the introduction of the C/T-13910 variant into Finnish population using DISLAMB program.
Marker AC3 LPH2 Allele Lactase Lactase non- Lactase Lactase non- persistence persistence persistence • persistence
1 0 1 0 1 2 31 10 0 20 3 0 1 0 14 4 2 9 32 15 5 0 31 0 2 λa 0.838 0.999
Θb 0.00031 (0,000038-0.00099) 0.0000(0.00000-0.00052)
570 450
a: λ is the proportion of increase of a certain allele in disease chromosomes (lactase
persistence allele) relative to its population frequency( 0.60). b: Θ is the
recombination fraction , reflected by the distance of the mutation from the closest marker, assuming lcM= 1Mb. C: n is the number of generation since the introduction of the founder mutation into a population Applying λ= °= (1-Θ)n formula, d:
Hypothetical allele used in the calculations as Θ is zero and °= is one.
Table 7 Prevalence of lactose intolerance variants in biochemically verified samples
C/T 13910 G/A ■22018
Number
Population CC CT TT GG GA AA
1. Finnish
Lactase persistence 182 0 95 87 0 95 87 Lactase non-persistence 116 116 0 0 110 6 0
2. Italian
Lactase persistence 7 0 7 0 0 7 0 Lactase non-persistence 23 23 0 0 22 1 0
3. German
Lactase persistence 0 0 0 0 0 0 0 Lactase non-persistence 8 8 0 0 8 0 0
4. Somalian
Lactase persistence 0 0 0 0 0 0 0 Lactase non-persistence 42 42 0 0 42 0 0
6. South koreans
Lactase persistence 0 0 0 0 0 0 0 Lactase non-persistence 23 23 0 0 23 0 0
Total 401 212 102 87 205 109 87
Table S> Prevalence of lactose-intolerance variants ϊn various population samples
Population Genotype %Prevalence
Number GJT13910 G/A22018 of Lactase
Persistence allele
CC CT TT GG GA AA
South Koreans 23 23 0 0 23 0 0 0 *
France 17 7 9 1 6 10 1 59 *
Basques 85 7 44 34 13 35 37 92 *
Southern Italians 100 89 1 1 0 88 12 0 1 1 *
Somalians 79 74 5 0 78 1 0 6
Utah 92 7 33 52 7 30 55 92 *
AfricanAmericans 96 76 15 5 78 12 5 21 *
Marrocans 90 62 25 3 65 22 3 31 *
Sarawhi (African) 57 29 26 2 28 26 3 49 *
Saami 30 20 10 0 21 9 0 33 *
Tibet 23 23 0 0 23 0 0 0
Eastern Finnish 571 108 287 176 107 288 176 81 *
Western Finnish 367 62 159 146 58 161 148 83 *
Finn-ugrian tribes
Xan 20 19 1 0 19 1 0 5
Xm 20 19 1 0 19 1 0 5
Mansi 22 20 2 0 20 2 0 9
Lkomi 10 7 3 0 7 3 0 30
Erza 30 17 10 3 19 9 2 43
Moksa 30 13 17 0 14 16 0 57 *
Udmort 30 12 16 2 1 1 15 4 60 *
Pakistanian tribes
Kalash 30 30 0 0 28 0 0
Burusho 30 29 1 0 27 3 0 3
Hazara 14 13 1 0 1 1 3 0 7
Kashmiri 20 15 5 0 14 6 0 25
Makrani Baluch . 29 19 10 0 19 8 1 34
Brahui 30 17 10 3 16 1 1 3 43
Makrani (Negroid) 29 16 10 3 16 10 3 45 H ω
Pathan 29 12 16 1 13 14 2 59 r
CD
Indian 29 1 1 13 5 10 12 5 62 CO o o
Total 2032 ■ zs
*The prevelance of lactase persistence allele is correlated very well with the reported prevelances for the lactase persistence allele (Simoons Fj. The geographic hypothesis and lactose malabsorption Am J Dig Dis 1978 23 (11):963-80)
Claims
1. A nucleic acid molecule comprising a 5' portion of an intestinal lactase- phlorizine hydrolase (LPH) gene contributing to or indicative of aduit-type hypolactasia wherein said nucleic acid molecule is selected from the group consisting of
(a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1 , the sequence of SEQ ID NO:1 is also depicted in Fig. 4 and comprised in the sequence as depicted in Fig. 8;
(b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 2, the sequence of SEQ ID NO:2 is also depicted in Fig. 5 and comprised in the sequence as depicted in Fig. 9;
(c) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 5' from the LPH gene a cytosine residue; and
(d) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 5' from the LPH gene a guanine residue.
2. A nucleic acid molecule comprising a 5' portion of an intestinal lactase- phlorizine hydrolase (LPH) gene wherein said nucleic acid molecule is selected from the group consisting of
(a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO:3, the sequence of SEQ ID NO:3 is also depicted in Fig. 6;
(b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO:4, the sequence of SEQ ID NO:4 is also depicted in Fig. 7;
(c) a nucleic acid molecule the complementary strand of which hybridizes
under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 of the LPH gene a thymidine residue; and (d) a nucleic acid molecule the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 of the LPH gene a adenosine residue.
3. The nucleic acid molecule of claim 1 or 2 which is genomic DNA.
4. The nucleic acid molecule of claim 3 wherein said genomic DNA is part of a gene.
5. A fragment of the nucleic acid molecule of any one of claims 1 to 4 having at least 14 nucleotides wherein said fragment comprises nucleotide position - 13910 or nucleotide position -22018 of the LPH gene.
6. A nucleic acid molecule which is complementary to the nucleic acid molecule of any one of claims 1 and 3 to 5.
7. A nucleic acid molecule which is complementary to the nucleic acid molecule of any one of claims 2 to 5.
8. A vector comprising the nucleic acid molecule of any one of claim 1 and 3 to 5.
9. A vector comprising the nucleic acid molecule of any one of claims 2 to 4.
10. A primer or primer pair, wherein the primer or primer pair hybridizes under stringent conditions to the nucleic acid molecule of any one of claims 1 and 3 to 5 comprising nucleotide position -13910 or -22018 of the LPH gene or to the complementary strand thereof.
11. A primer or primer pair, wherein the primer or primer pair hybridizes under stringent conditions to the nucleic acid molecule of any one of claims 2 to 5 comprising nucleotide position -13910 or -22018 of the LPH gene or to the complementary strand thereof.
12. A non-human host transformed with the vector of claim 6.
13. A non-human host transformed with the vector of claim 7.
14. The non-human host of claim 12 or 13 which is a bacterium, a yeast cell, an insect cell, a fungal cell, a mammalian cell, a plant cell, a transgenic animal or a transgenic plant.
15. An antibody or aptamer or phage that specifically binds to the wild-type nucleic acid molecule of any one of claims 1 and 3 to 6 but not to the corresponding wild-type nucleic acid molecule
16. An antibody or aptamer or phage that specifically binds to the wild-type nucleic acid molecule of any one of claims 2 to 5 and 7 but not to the corresponding mutant sequence contributing to or indicative of adult-type hypolactasia.
7. A pharmaceutical composition comprising the wild-type nucleic acid molecule of claim 2, 3, 4 or the vector of claim 9.
18. A diagnostic composition comprising the nucleic acid molecule of any one of claims 1 to 7, the vector of claim 8 or 9, the primer or primer pair of claim 11 or 12, and/or the antibody aptamer and/or phage of claim 15 or 16.
19. A method for testing for the presence or predisposition of adult-type hypolactasia or associated trait comprising testing a sample obtained from a prospective patient or from a person suspected of carrying such a predisposition for the presence of the nucleic acid molecule of any one of claims 1 and 3 to 6 in a homozygous or heterozygous state.
20. A method for testing for the presence or predisposition of adult-type hypolactasia or associated trait comprising testing a sample obtained from a prospective patient or from a person suspected of carrying such a predisposition for the presence of the nucleic acid molecule of any one of claims 2 to 5 and 7 in a homozygous or heterozygous state.
21. The method of claim 19 or 20, wherein said testing comprises hybridizing the complementary nucleic acid molecule of claim 6 which is complementary to the nucleic acid molecule contributing to or indicative of adult-type hypolactasia or the nucleic acid molecule of claim 7 which is complementary to the wild-type sequence as a probe under stringent conditions to nucleic acid molecules comprised in said sample and detecting said hybridization.
22. The method of any one of claims 19 or 21 further comprising digesting the product of said hybridization with a restriction endonuclease or subjecting the product of said hybridization to digestion with a restriction endonuclease and analyzing the product of said digestion.
23. The method of claim 21 , wherein said probe is detectably labeled.
24. The method of claim 19 or 20, wherein said testing comprises determining the nucleic acid sequence of at least a portion of the nucleic acid molecule of any one of claims 1 to 7, said portion comprising nucleotide position -13910 and/or nucleotide position -22018 of the LPH gene.
25. The method of claim 24, wherein the determination of the nucleic acid sequence is effected by solid-phase minisequencing.
26. The method of claim 24 further comprising, prior to determining said nucleic acid sequence, amplification of at least said portion of said nucleic acid molecule.
27. The method of claim 19 or 20, wherein said testing comprises carrying out an amplification reaction wherein at least one of the primers employed in said amplification reaction is the primer of claim 10 or belongs to the primer pair of claim 10, comprising assaying for an amplification product.
28. The method of claim 19 or 20, wherein said testing comprises carrying out an amplification reaction wherein at least one of the primers employed in said amplification reaction is the primer of claim 11 or belongs to the primer pair of claim 11 , comprising assaying for an amplification product.
29. The method of any one of claims 26 to 28 wherein said amplification is effected by or said amplification is the polymerase chain reaction (PCR).
30. A method for testing for the presence or predisposition of adult-type hypolactasia comprising assaying a sample obtained from a human for specific binding to the antibody or aptamer or phage of claim 15
31. A method for testing for the presence or predisposition of adult-type hypolactasia comprising assaying a sample obtained from a human for specific binding to the antibody or aptamer or phage of claim 16.
32. The method of claim 30 or 31 , wherein said antibody or aptamer or phage is detectably labeled.
33. The method of any one of claims 30 to 32, wherein the test is an immuno- assay.
34. The method of any one of claims 19 to 33, wherein said sample is blood, serum, plasma, fetal tissue, saliva, urine, mucosal tissue, mucus, vaginal tissue, fetal tissue obtained from the vagina, skin, hair, hair follicle or another human tissue.
35. The method of any one of claims 19 to 34, wherein said nucleic acid molecule from said sample is fixed to a solid support.
36. The method of claim 35, wherein said solid support is a chip, a silica wafer, a bead or a microtiter plate.
37. Use of the nucleic acid molecule of any one of claims 1 to 7 for the analysis of the presence or predisposition of adult-type hypolactasia.
38. Kit comprising the nucleic acid molecule of any one of claims 1 to 7, the primer or primer pair of claim 11 or 12, the vector of claim 8 or 9, and/or the antibody aptamer and/or phage of claim 15 or 16 in one or more containers.
39. Use of the nucleic acid molecule of any one of claims 2 to 4 or the vector of claim 7 in gene therapy.
40. The use of claim 39, wherein said gene therapy treats or prevents adult-type hypolactasia.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2456516A CA2456516C (en) | 2001-08-10 | 2002-08-09 | Identification of a dna variant associated with adult type hypolactasia |
| MXPA04001279A MXPA04001279A (en) | 2001-08-10 | 2002-08-09 | Identification of a dna variant associated with adult type hypolactasia. |
| ES02794596T ES2391173T3 (en) | 2001-08-10 | 2002-08-09 | Identification of a DNA variant associated with adult hypolactasis |
| AU2002355471A AU2002355471B2 (en) | 2001-08-10 | 2002-08-09 | Identification of a DNA variant associated with adult type hypolactasia |
| IL16015102A IL160151A0 (en) | 2001-08-10 | 2002-08-09 | Identification of a dna variant associated with adult type hypolactasia |
| CN02815708.7A CN1541265B (en) | 2001-08-10 | 2002-08-09 | Identification of DNA variant associated with adult type hypolactasia |
| EP02794596A EP1417305B1 (en) | 2001-08-10 | 2002-08-09 | Identification of a dna variant associated with adult type hypolactasia |
| JP2003519472A JP4521184B2 (en) | 2001-08-10 | 2002-08-09 | Identification of DNA variants associated with adult lactase deficiency |
| DK02794596.3T DK1417305T3 (en) | 2001-08-10 | 2002-08-09 | Identification of a DNA variant associated with acquired lactose intolerance |
| US10/775,501 US8252537B2 (en) | 2001-08-10 | 2004-02-09 | Identification of a DNA variant associated with adult type hypolactasia |
| HK05103606.5A HK1070918A1 (en) | 2001-08-10 | 2005-04-27 | Identification of a dna variant associated with adult type hypolactasia dna |
| US13/594,731 US10144979B2 (en) | 2001-08-10 | 2012-08-24 | Identification of a DNA variant associated with adult type hypolactasia |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01119377.8 | 2001-08-10 | ||
| EP01119377 | 2001-08-10 | ||
| EP01119528.6 | 2001-08-14 | ||
| EP01119528 | 2001-08-14 | ||
| US31595501P | 2001-08-31 | 2001-08-31 | |
| US60/315,955 | 2001-08-31 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/775,501 Continuation US8252537B2 (en) | 2001-08-10 | 2004-02-09 | Identification of a DNA variant associated with adult type hypolactasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003014342A2 true WO2003014342A2 (en) | 2003-02-20 |
| WO2003014342A3 WO2003014342A3 (en) | 2003-12-18 |
Family
ID=35611633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2002/008963 WO2003014342A2 (en) | 2001-08-10 | 2002-08-09 | Identification of a dna variant associated with adult type hypolactasia |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1417305B1 (en) |
| JP (1) | JP4521184B2 (en) |
| CN (1) | CN1541265B (en) |
| AU (1) | AU2002355471B2 (en) |
| CA (1) | CA2456516C (en) |
| DK (1) | DK1417305T3 (en) |
| ES (1) | ES2391173T3 (en) |
| MX (1) | MXPA04001279A (en) |
| PT (1) | PT1417305E (en) |
| RU (1) | RU2391404C2 (en) |
| WO (1) | WO2003014342A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109880901A (en) * | 2019-04-24 | 2019-06-14 | 杭州云鼎基因生物科技有限公司 | The detection method in lactose metabolism associated gene mutation site |
-
2002
- 2002-08-09 AU AU2002355471A patent/AU2002355471B2/en not_active Expired
- 2002-08-09 WO PCT/EP2002/008963 patent/WO2003014342A2/en active Application Filing
- 2002-08-09 RU RU2004107086/15A patent/RU2391404C2/en active
- 2002-08-09 EP EP02794596A patent/EP1417305B1/en not_active Expired - Lifetime
- 2002-08-09 JP JP2003519472A patent/JP4521184B2/en not_active Expired - Lifetime
- 2002-08-09 MX MXPA04001279A patent/MXPA04001279A/en active IP Right Grant
- 2002-08-09 ES ES02794596T patent/ES2391173T3/en not_active Expired - Lifetime
- 2002-08-09 CA CA2456516A patent/CA2456516C/en not_active Expired - Lifetime
- 2002-08-09 PT PT02794596T patent/PT1417305E/en unknown
- 2002-08-09 DK DK02794596.3T patent/DK1417305T3/en active
- 2002-08-09 CN CN02815708.7A patent/CN1541265B/en not_active Expired - Lifetime
Non-Patent Citations (9)
| Title |
|---|
| BOLL W ET AL: "STRUCTURE OF THE CHROMOSOMAL GENE AND COMPLEMENTARY DNAS CODING FOR LACTASE PHLORIZIN HYDROLASE IN HUMANS WITH ADULT-TYPE HYPOLACTASIA OR PERSISTENCE OF LACTASE" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 48, no. 5, 1991, pages 889-902, XP009012268 ISSN: 0002-9297 * |
| DATABASE EMBL [Online] 26 April 2001 (2001-04-26) HARRINGTON J.J. ET AL.: "RST8055 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence." Database accession no. BG189020 XP002244249 * |
| DATABASE EMBL [Online] 11 November 1999 (1999-11-11) MAHAIRAS G.G. ET AL. : "HS_3081_B2_E03_T7C CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone" Database accession no. AQ892176 XP002244250 * |
| DATABASE EMBL [Online] 18 October 1999 (1999-10-18) SULSTON J.E. ET AL.: "Homo sapiens BAC clone RP11-34L23 from 2, complete sequence." Database accession no. AC011893 XP002244247 * |
| DATABASE EMBL [Online] 3 August 1999 (1999-08-03) MAHAIRAS G.G. ET AL.: "HS_3106_A2_D07_T7C CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone" Database accession no. AQ781670 XP002244251 * |
| DATABASE EMBL [Online] 5 May 1999 (1999-05-05) MAHAIRAS G.G. ET AL.: "HS_5237_A1_G08_SP6E RPCI-11 Human Male BAC Library Homo sapiens genomic clone" Database accession no. AQ515834 XP002244248 * |
| ENATTAH NABIL SABRI ET AL: "Identification of a variant associated with adult-type hypolactasia." NATURE GENETICS, vol. 30, no. 2, February 2002 (2002-02), pages 233-237, XP002244246 February, 2002 ISSN: 1061-4036 * |
| JARVELA IRMA ET AL: "Assignment of the locus for congenital lactase deficiency to 2q21, in the vicinity of but separate from the lactase-phlorizin hydrolase gene." AMERICAN JOURNAL OF HUMAN GENETICS, vol. 63, no. 4, October 1998 (1998-10), pages 1078-1085, XP002244245 ISSN: 0002-9297 * |
| WANG YANGXI ET AL: "The lactase persistence/non-persistence polymorphisms is controlled by a cis-acting element." HUMAN MOLECULAR GENETICS, vol. 4, no. 4, 1995, pages 657-662, XP009012156 ISSN: 0964-6906 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2456516C (en) | 2012-08-07 |
| WO2003014342A3 (en) | 2003-12-18 |
| CN1541265B (en) | 2014-09-10 |
| EP1417305A2 (en) | 2004-05-12 |
| ES2391173T3 (en) | 2012-11-22 |
| CN1541265A (en) | 2004-10-27 |
| AU2002355471B2 (en) | 2007-09-13 |
| MXPA04001279A (en) | 2005-06-06 |
| PT1417305E (en) | 2012-10-11 |
| EP1417305B1 (en) | 2012-07-18 |
| RU2004107086A (en) | 2005-04-10 |
| DK1417305T3 (en) | 2012-10-15 |
| JP4521184B2 (en) | 2010-08-11 |
| JP2005502336A (en) | 2005-01-27 |
| CA2456516A1 (en) | 2003-02-20 |
| RU2391404C2 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160265052A1 (en) | Gene for Identifying Individuals with Familial Dysautonomia | |
| US10144979B2 (en) | Identification of a DNA variant associated with adult type hypolactasia | |
| JP2003513620A (en) | Molecular structure of RHD negative locus | |
| AU2002355471B2 (en) | Identification of a DNA variant associated with adult type hypolactasia | |
| JP2004508003A (en) | Nucleic acids containing single nucleotide polymorphisms and methods of using the same | |
| AU2002355471A1 (en) | Identification of a DNA variant associated with adult type hypolactasia | |
| GB2372564A (en) | P2X7 polymorphisms | |
| AU2004247896B2 (en) | Mutations in the SLC40A1 gene associated to impaired iron homeostasis | |
| Bolino et al. | A new candidate region for the positional cloning of the XLP gene | |
| US7317097B2 (en) | Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis | |
| AU2001239837B2 (en) | Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions | |
| US9157119B2 (en) | Methods for diagnosing skin diseases | |
| US20070202502A1 (en) | Assay For Bipolar Affective Disorder | |
| US20040235026A1 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| US20190276891A1 (en) | Gene for identifying individuals with familial dysautonomia | |
| WO2001078575A2 (en) | Ext2 as a predictive marker for osteoporosis | |
| US20040161747A1 (en) | Method for screening for autoimmune disease by identifying polymorphisms in il-12 p40 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2002355471 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 160151 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2456516 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10775501 Country of ref document: US Ref document number: 2003519472 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001279 Country of ref document: MX Ref document number: 20028157087 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002794596 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002794596 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |